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Stopping Deceptive Health Claims: The Need for a Private Right of Action under Federal 
Law  
Diane E. Hoffmann∗ and Jack Schwartz∗∗ 
I. INTRODUCTION 
Consumers are currently facing a torrent of new health claims as they shop for food and 
dietary supplements (hereinafter referred to as “nutritional products”) in grocery stores, 
pharmacies, health food stores and on the Internet.1  Some of these products make claims that 
they support immunity, improve memory,2 and even cure cancer.3 Such claims appear to 
correspond to a growing consumer demand for foods and supplements that improve or maintain 
                                                 
∗ Professor of Law and Director, Law and Health Care Program, University of Maryland Francis King Carey School 
of Law. 
∗∗ Adjunct Professor and Senior Research Associate, University of Maryland Francis King Carey School of Law; 
Maryland Ass’t Attorney General 1982–2008, as Chief Counsel for Opinions and then the Director of Health Policy 
Development. 
1 See, e.g., Editors, Snake Oil in the Supermarket, SCIENTIFIC AMERICAN (Aug. 1, 2010), 
http://www.scientificamerican.com/article/snake-oil-in-the-supermarket/ (stating that “[f]rom cereals that boost 
immunity to yogurts that regulate digestion and juices that keep heart disease at bay, grocery stores in the U.S. are 
brimming with packaged foods and beverages that claim to improve health”); see also Caitlin Y. Kandil, What Food 
Labels Really Mean, U.S. NEWS & WORLD REPORT HEALTH (Aug. 22, 2012), http://health.usnews.com/health-
news/articles/2012/08/22/what-food-labels-really-mean (stating that you can “[w]alk into any supermarket, and 
you’ll find rows of packaged foods boasting how healthy they are”). 
2 See Michael Taylor, How the FDA Is Picking its Food Label Battles, THE ATLANTIC (July 19, 2010), 
http://www.theatlantic.com/health/print/2010/07/how-the-fda-is-picking-its-food-label-battles/59927/.  
3 See David C. Vladeck, Director, Fed. Trade Comm’n Bureau of Consumer Protection, Remarks at the Annual 
Symposium for the Dietary Supplement Industry: Priorities for Dietary Supplement Advertising Enforcement 4 
(Oct. 22, 2009), http://www.thenhf.com/pdf/VladedckCRNRemarks.pdf. 
2 
 
health and wellness.4 A 2004 survey of U.S. consumers found that purchasing decisions in the 
food and dietary supplement markets “are guided almost entirely by product labeling claims.”5  
Among the most persuasive of these are “claims that consumption may confer health benefits.”6  
Claims about health benefits are more persuasive to consumers when they appear to be 
authoritative. The problem with seemingly authoritative claims, however, is that most of them 
are neither based on rigorous clinical studies nor vetted by any government agency.7 Some lack 
                                                 
4 In the food arena, these products have been referred to as functional foods, i.e., foods that have a “potentially 
positive effect on health beyond basic nutrition.” Katherine Zeratsky, Nutrition and Healthy Eating: What are 
Functional Foods?, MAYO CLINIC (Apr. 11, 2015), http://www.mayoclinic.org/healthy-living/nutrition-and-healthy-
eating/expert-answers/functional-foods/faq-20057816. See also infra notes 37-44 and accompanying text.  
5 Leah A. Satine, Is My Yogurt Lying? Developing and Applying a Framework for Determining Whether Wellness 
Claims on Probiotic Yogurts Mislead, 63 FOOD & DRUG L.J. 537, 537 (2008).   
6 Id. at 538. The Academy of Nutrition and Dietetics links the growing demand for these nutritional products to 
rising health-care costs and scientific research supporting a connection between a good diet and a lower incidence of 
chronic disease. See Consumers Union of U.S. Inc., ‘Functional Food’ is Hot, but its Claims of Health Benefits Rely 
on Flimsy Data, WASH. POST (June 18, 2012), http://www.washingtonpost.com/national/health-science/functional-
food-is-hot-but-its-claims-of-health-benefits-rely-on-flimsy-data/2012/06/18/gJQAWmxflV_story.html. 
7See Matthew Herper & Rebecca Ruiz, Snake Oil in Your Snacks, FORBES (May 20, 2010), 
http://www.forbes.com/forbes/2010/0607/health-probiotics-vitamins-supplements-snake-oil-in-snacks.html; see also 
Rahi Azizi, “Supplementing” the DSHEA: Congress Must Invest the FDA with Greater Regulatory Authority over 
Nutraceutical Manufacturers by Amending the Dietary Supplement Health and Education Act, 98 CAL. L. REV. 439, 
440 (2010) (“‘Nutraceutical’ products—functional foods taken to enhance health, like vitamins or herbal and 
botanical products intended for ingestion—often carry labels that claim ambiguous benefits, but fail to demonstrate 
any measurable degree of efficacy.”).  
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any evidence of effectiveness;8 others go beyond what is permitted by law.9 Although this 
problem has been recognized for some while,10 it is compounded by the vigorous marketing of 
new product lines, such as probiotics, claiming a wide variety of health benefits.11  The growing 
market for these new products,12 coupled with lack of reliable studies of their efficacy,13 create 
additional challenges for consumers and regulators.14 
                                                 
8 See OFFICE OF INSPECTOR GEN., U.S. DEP’T OF HEALTH & HUMAN SERVICES, DIETARY SUPPLEMENTS: COMPANIES 
MAY BE DIFFICULT TO LOCATE IN AN EMERGENCY (Oct. 2012), https://oig.hhs.gov/oei/reports/oei-01-11-00211.pdf.  
See also Herper & Ruiz, supra note 7; see also Azizi, supra note 7. 
9 Vladeck, supra note 3, at 2 (stating that “[s]ome marketers of dietary supplements make disease treatment and 
prevention claims that far exceed the bounds of the structure/function claims that are permitted under the Dietary 
Supplement Health and Education Act (DSHEA)”). See also OFFICE OF INSPECTOR GEN., U.S. DEP’T OF HEALTH & 
HUMAN SERVICES, DIETARY SUPPLEMENTS: STRUCTURE/FUNCTION CLAIMS FAIL TO MEET FEDERAL REQUIREMENTS 
(Oct. 2012), https://oig.hhs.gov/oei/reports/oei-01-11-00210.pdf [hereinafter STRUCTURE/FUNCTION CLAIMS FAIL]; 
U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-10-662T, HERBAL DIETARY SUPPLEMENTS: EXAMPLES OF DECEPTIVE 
OR QUESTIONABLE MARKETING PRACTICES AND POTENTIALLY DANGEROUS ADVICE (May 26, 2010), 
http://www.gao.gov/new.items/d10662t.pdf (testimony of Gregory D. Kutz, Managing Dir., Forensic Audits and 
Special Investigations, U.S. Gov’t Accountability Office) [hereinafter Testimony of Gregory D. Kutz]. 
10 See, e.g., Norman J. Temple, The Marketing of Dietary Supplements in North America: The Emperor is (Almost) 
Naked, 16 J. ALTERNATIVE & COMPLEMENTARY MED. 803 (2010). 
11 Probiotics are products with live microorganisms that can confer a health benefit. See JOINT FOOD AND 
AGRICULTURE ORG. OF THE U.N./WORLD HEALTH ORG. EXPERT CONSULTATION, REPORT: HEALTH AND 
NUTRITIONAL PROPERTIES OF PROBIOTICS IN FOOD INCLUDING POWDER MILK WITH LIVE LACTIC ACID BACTERIA 
(Oct. 1-4, 2001), ftp://ftp.fao.org/es/esn/food/probio_report_en.pdf. 
12 See Nandhini Rajagopal, The North American Probiotics Market, NATURAL PRODUCTS INSIDER (Oct. 3, 2012), 
http://www.naturalproductsinsider.com/articles/2012/10/the-north-american-probiotics-market.aspx. See also Vijaya 
K. Gogineni et al., Probiotics: History and Evolution, J. ANCIENT DISEASES & PREVENTIVE REMEDIES (Aug. 2013), 
http://esciencecentral.org/journals/probiotics-history-and-evolution-2329-8731.1000107.pdf; Keith Nunes, United 
4 
 
Preventing deceptive claims15 about the health-related benefits of nutritional products is an 
important goal of federal and state consumer protection policy. Promoting nutritional products 
through deceptive claims can cause a variety of harms. The most obvious is the financial 
exploitation of consumers through deceptively induced sales. Even more troubling is the 
potential for harm by giving consumers false hope that nutritional products are the best response 
to health problems. In the case of some nutritional products, Internet ads claim that they can 
improve symptoms related to serious illnesses, including chronic diseases or chronic pain.16 Such 
                                                                                                                                                             
States Poised to Lead Functional Food Market, FOOD BUS. NEWS (Dec. 10, 2014), 
http://www.foodbusinessnews.net/articles/news_home/Business_News/2014/12/United_States_poised_to_lead_f.asp
x?ID=%7B3E104CB5-F892-46A3-B989-4A798CBB1B66%7D&cck=1 (stating that the leading product categories 
that will help the U.S. surpass Japan as the number one consumer of functional foods in the world is dairy foods that 
contain probiotics and products containing whole grains). 
13 See Gregor Reid et al., Potential Uses of Probiotics in Clinical Practice, 16 CLINICAL MICROBIOLOGY REVIEWS 
658 (2003) (stating that “[m]any so-called probiotic products have not been properly identified, documented, 
manufactured under good manufacturing practices or proven clinically, yet various companies make claims that lead 
consumers and caregivers to believe they are using reliable products” ). 
14 See Melody J. Slashinski et al., “Snake-oil,” “Quack Medicine,” and “Industrially Cultured Organisms”: 
Biovalue and the Commercialization of Human Microbiome Research, BMC MED. ETHICS (Oct. 2012), 
http://www.biomedcentral.com/content/pdf/1472-6939-13-28.pdf.  
15 In this article, we use the general term “deceptive” to encompass the making of express or implied health claims 
that are false, misleading, or unsupported by competent and reliable scientific evidence. The term “unsubstantiated” 
refers to the last of these unlawful practices. See generally U.S. FED. TRADE COMM’N, ENFORCEMENT POLICY 
STATEMENT ON FOOD ADVERTISING (May 13, 1994), https://www.ftc.gov/public-statements/1994/05/enforcement-
policy-statement-food-advertising. 
16 In remarks to Congress, David Vladeck, former Director of the FTC Bureau of Consumer Protection, stated that 
“Consumers suffering from serious health ailments are particularly vulnerable and sometimes desperate. The 
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claims might lead consumers to forgo medically recommended therapies. Consumers who are 
taking prescription drugs face the additional risk that some of these products, in particular dietary 
supplements, may result in harmful interactions.17   
Claims made by foods and dietary supplement manufacturers are regulated by both the Food 
and Drug Administration (FDA) and the Federal Trade Commission (FTC).18 FDA regulates 
labeling, while the FTC regulates advertising.19 Under the Food, Drug and Cosmetic (FD&C) 
Act, labels on these products must not be false or misleading.20 Under the FTC Act, claims in 
advertising made about foods and dietary supplements may not be “unfair” or “deceptive”.21  
While FDA and the FTC have made some efforts to challenge companies making deceptive 
health claims,22 lack of resources for enforcement, the difficulty of policing advertising on the 
                                                                                                                                                             
marketing of unfounded treatments to such people offers a type of false hope that is particularly cruel.” Vladeck, 
supra note 3. Vulnerable populations often include senior citizens and adolescents. See Azizi, supra note 7, at 447.  
17 See H-H. Tsai et al., Evaluation of Documented Drug Interactions and Contraindications Associated with Herbs 
and Dietary Supplements: A Systematic Literature Review, 66 INT’L J. CLINICAL PRACTICE 1056 (2012). 
18 See infra Section III.  
19 Advertisements include claims made in newspapers and magazines, on television or radio, online, in the mail, or 
on billboards or buses. See Truth in Advertising, U.S. FED. TRADE COMM’N, www.ftc.gov/news-events/media-
resources/truth-advertising (last visited Aug. 18, 2015). 
20 See 21 U.S.C. § 343(a) (2012); see also infra Section III.A.   
21 See 15 U.S.C. § 45(a)(1) (2012); see also infra Section III.B. 
22 See, e.g., Vladeck, supra note 3; Taylor, supra note 2. See also Sarah Klein, POM-boozled: Do Health Drinks 
Live Up to Their Labels?, CNN HEALTH (Oct. 27, 2010), 
http://www.cnn.com/2010/HEALTH/10/27/health.pom.drink.labels/ (noting that the FTC and FDA have been 




Internet, and the lure of profit by food and dietary supplement manufacturers make it virtually 
impossible for FDA and the FTC to keep pace with the marketing strategies for these products.23  
Moreover, FDA’s regulatory power over these manufacturers has actually declined over the last 
few decades due to limitations placed on the agency by Congress and the courts.24  In addition, it 
is unlikely that these enforcement mechanisms adequately deter “quick hit” marketers 
unconcerned about long-term business or reputation. 
In order to bolster the enforcement tools available to combat the problem of deceptive health 
claims for nutritional products, we propose a limited private right of action under the Federal 
Trade Commission Act.  As background to this proposal, in Section II of this article we expand 
on the problem of deceptive health claims for foods and dietary supplements amidst the growing 
demand for these products. In Section III, we describe the current legal standards under the 
FD&C and FTC Acts and state consumer protection laws governing deceptive claims made by 
nutritional product manufacturers and current enforcement efforts aimed at ensuring compliance 
with the laws.  In Section IV, we describe the limits of existing law and enforcement capabilities 
of the relevant federal agencies as well as the limits and shortcomings of state laws and their use 
by consumers. In Section V, we describe the benefits, risks and contours of the proposed limited 
private right of action, with an emphasis on creating an approach that will augment existing 
enforcement tools and lead to more effective consumer protection without undermining 
important federal agency control and enforcement goals. In Appendix A, we offer suggested 
                                                 
23 See Natasha Singer, Foods With Benefits, or So They Say, N.Y. TIMES (May 14, 2011), 
http://www.nytimes.com/2011/05/15/business/15food.html; see also infra Section IV.  
24 See Editors, supra note 1. See also David Vinjamuri, POM Wonderful’s Deception is the Tip of the Iceberg, 
FORBES (May 23, 2012), http://www.forbes.com/sites/davidvinjamuri/2012/05/23/judge-finds-pom-wonderful-
advertising-deceptive-but-thats-just-the-tip-of-the-iceberg/; infra Section IV.  
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language for a statutory amendment to the FTC Act establishing the proposed private right of 
action. 
 
II. THE PROBLEM OF DECEPTIVE CLAIMS IN THE MARKETING OF NUTRITIONAL 
PRODUCTS 
Several prominent news stories have reported a growing prevalence of deceptive health 
claims for nutritional products sold at grocery and drug stores.25 For example, a 2011 New York 
Times article quotes consumer advocates and nutritionists as stating that “shoppers are being 
bamboozled by slick marketing” of these products and that these products are not about health, 
but about marketing.26 Similarly, a 2010 Scientific American article warned consumers that many 
supermarket health claims are not supported by science and the government does not endorse 
them.27 These articles and others provide numerous examples of companies that lack 
substantiation for their claims or even ignore evidence that shows their product clearly does not 
do what they claim it does.28 The claims are being made for two types of products:  foods with 
                                                 
25 See Consumers Union of U. S. Inc., supra note 6; Singer, supra note 23; Herper & Ruiz, supra note 7; Matthew 
Herper, Wacky Food Health Claims, FORBES (May 19, 2010) http://www.forbes.com/2010/05/19/food-claims-
supplements-lifestyle-health-yogurt-margarine.html; Gyorgy Scrinis, That’s Not Natural or Organic: How Big Food 
Misleads, SALON (July 20, 2013), 
http://www.salon.com/2013/07/20/thats_not_natural_or_organic_how_big_food_misleads/; Garance Burke, Many 
Health Supplement Claims Misleading, Illegal, WASH. TIMES (Oct. 3, 2012), 
http://www.washingtontimes.com/news/2012/oct/3/many-health-supplement-claims-misleading-illegal/?page=all.  
26 Singer, supra note 23.  
27 Editors, supra note 1.  
28 See Herper & Ruiz, supra note 7 (describing how Lifeway Foods, the maker of Probugs, a yogurt-like beverage 
for kids, ignored clinical trials results in making its claims). 
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alleged health benefits (also called functional foods29); and dietary supplements, such as 
vitamins, minerals, and herbs, intended to add nutritional value to the diet. Both consumer 
groups and government agencies have weighed in on the extent of the problem.  
The Center for Science in the Public Interest (CSPI), a consumer advocacy organization with 
a mission to carry out “innovative research and advocacy programs in health and nutrition, and to 
provide consumers with current, useful information about their health and well-being,”30 has 
made food labeling and deceptive health claims a priority in its advocacy program. In April 
2013, the organization initiated its “Stop the Lying Labels” campaign.31  In an email to members 
of a CSPI listserv, Michael Jacobson, the organization’s executive director, stated that in his 
forty-plus years of dealing with the food industry, he has “never encountered such bold 
deception and disregard for the law” as he sees now in the area of food labeling.32 
                                                 
29 See Zeratsky, supra note 4. 
30 Mission Statement, CTR. FOR SCIENCE IN THE PUB. INTEREST, http://cspinet.org/about/mission.html (last visited 
Aug. 18, 2015). 
31 Michael F. Jacobson, CSPI’s Year-End Report to the Membership, CTR. FOR SCIENCE IN THE PUB. INTEREST (Nov. 
7, 2013), http://cspinet.org/about/CSPI-Year-End-Report-2013.pdf. 
32 E-mail from Michael Jacobson, Exec. Dir., Ctr. for Science in the Pub. Interest, to Diane Hoffmann, Professor of 
Law, Univ. Maryland Francis King Carey School of Law (Apr. 29, 2013, 08:31 EST) (on file with author). Jacobson 
provides the following examples: “General Mills’ false claims that some of its corn-syrup-drenched products are 
‘natural’. . . Coca-Cola Company’s deceptive health claims about its Vitamin water (which would be better called 
Sugar water). . . Amway’s deceptive claims about “immunity system boosters” in its Nutrilite products (which do 
nothing to boost your immunity). . . Campbell’s misleading labeling about sodium in its soups by pretending that 
people consume smaller serving sizes . . . and Dr. Pepper Snapple group’s made-up claims of benefits from the 
antioxidants it adds to some of its 7UP sugar drinks, which promote obesity, not health.” Id. 
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Similarly, government reports and statements have been critical of claims being made by 
dietary supplement manufacturers—in particular, structure/function claims.33  The criticism is 
that these claims go outside the bounds of the regulatory limits on them and bleed into the 
disease claim (i.e., drug) category,34 thus requiring premarketing approval by FDA, or that 
manufacturers have not done the studies necessary to substantiate their claims.  In 2010, the 
Government Accountability Office (GAO) issued a report in which it described numerous 
examples of deceptive or questionable marketing practices by dietary supplement manufacturers 
and retailers. Most egregious of the practices they found were suspect claims that a dietary 
supplement “prevented or cured extremely serious diseases, such as cancer and cardiovascular 
diseases” or that it reduced the symptoms of Alzheimer’s disease.35  
The FTC has also asserted that the food and dietary supplement industries are making health 
claims that are often “false or unproven.” In particular, the agency cites a “trend in food 
advertising toward making unproven claims that eating certain foods can improve health and 
even reduce the risk of serious illnesses such as prostate cancer and heart disease.”36  
                                                 
33 These are “statements that describe the role of a nutrient or dietary ingredient intended to affect the structure or 
function in humans or that characterize the documented mechanism by which a nutrient or dietary ingredient acts to 
maintain such structure or function . . . .” 21 C.F.R. § 101.93(f) (2014). See infra notes 78-82 and accompanying 
text. 
34 See U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: STRUCTURE/FUNCTION CLAIMS, SMALL ENTITY 
COMPLIANCE GUIDE (Jan. 9, 2002), 
http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/DietarySupplements/uc
m103340.htm.  See infra notes 60 and 61 and accompanying text. 
35 Testimony of Gregory D. Kutz, supra note 10. 
36 Health and Fitness Claims, FED. TRADE COMM’N, https://www.ftc.gov/news-events/media-resources/truth-
advertising/health-claims (last visited Aug. 18, 2015). 
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While there is little hard evidence of the extent of the problem, a walk through a supermarket 
or pharmacy reveals the pervasiveness of health claims on product labels. Moreover, the growing 
demand for these products suggests that the problem will increase over the next several years.  
Markets for both dietary supplements and functional foods are booming. A 2012 Department of 
Health and Human Services (DHHS) Office of Inspector General (OIG) report on 
structure/function claims about dietary supplements states that in this country, “dietary 
supplements are a $20 billion-per-year industry and are used by 80 percent of adults for a wide 
range of purposes.”37 The worldwide market for these products is also flourishing. According to 
a 2013 article in Forbes, “[o]ne of the fastest growing industries in the world is the nutritional 
supplement group. . . . Producing about $32 billion in revenue for just nutritional supplements 
alone in 2012, it is projected to double that by topping $60 billion in 2021.”38 The FTC suggests 
on its website that consumers have turned to supplements as a result of a “downturn in the 
economy” and as a way to “avoid expensive doctor visits and prescription medications.”39 
                                                 
37 STRUCTURE/FUNCTION CLAIMS FAIL, supra note 9, at 1 (citing Natural Products Foundation, What is the Current 
Economic Contribution of the Dietary Supplement Industry to the U.S. Economy?, NATURAL PRODUCTS FOUND. 
(rev. Mar. 2011), https://www.npainfo.org/App_Themes/NPA/docs/policy/Econ%20One%20sheet%203-
11%20final.pdf). See also Farin Kamangar & Ashkan Emadi, Vitamin and Mineral Supplements: Do We Really 
Need Them?, 3 INT’L J. PREVENTIVE MED. 221 (2012) (estimating total sales of nutritional supplements in the 
United States in 2010 to have been over $28 billion). 
38 David Lariviere, Nutritional Supplements Flexing Muscles as Growth Industry, FORBES (Apr. 18, 2013), 
http://www.forbes.com/sites/davidlariviere/2013/04/18/nutritional-supplements-flexing-their-muscles-as-growth-
industry/ (citing figures from the Nutritional Business Journal). 
39 Health and Fitness Claims, supra note 36. 
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The market for functional foods and beverages is growing at an even greater rate than dietary 
supplements, with the global market for these products reaching over $170 billion in 2013.40 
According to one source, “this booming category now accounts for 5% of the overall food 
market and is driving growth for the food industry as a whole.”41  This same source also 
attributes this sales growth to consumers looking to these products as a health solution. In 
particular, consumers are looking to functional foods as a way to manage “chronic conditions, 
such as diabetes, [cardio-vascular disease] or obesity.”42 Claimed benefits of these foods include 
boosting energy levels, improving or maintaining gut, bone and heart health, managing weight, 
and sharpening mental faculties.43 One of the fastest growing segments of both the dietary 
supplement and functional food markets is probiotics, in large part due to manufacturers’ claims 
for the role of probiotics in wellness and health improvement.44  
                                                 
40 Maggie Hennessy, What’s Driving Growth in Functional Food and Beverages? A Convergence of Nutrition, 





43 PRICE WATERHOUSE COOPERS, LEVERAGING GROWTH IN THE EMERGING FUNCTIONAL FOODS INDUSTRY: TRENDS 
AND MARKET OPPORTUNITIES 9 (Aug. 2009), http://www.pwc.com/us/en/transaction-
services/publications/assets/functional-foods.pdf. 
44 See Hank Schultz, Supplement Sales Hit $11.5 Billion in U.S., Report Says, NUTRAINGREDIENTS-USA.COM (Sept. 
20, 2012), http://www.nutraingredients-usa.com/Markets/Supplement-sales-hit-11.5-billion-in-U.S.-report-says 
(stating that in terms of different segments of the dietary supplement market, “digestive supplements are doing very 
well right now, especially probiotics”).  See also International Probiotics (Functional Foods, Dietary Supplements, 
Specialty Nutrients, Animal Feed) Market – Forecasts to 2019, MARKETWIRED (July 2, 2014), 
12 
 
The functional food market consists of a number of large multinational companies,45 but 
smaller participants are “successfully creating and defending niches in the market.”46 Large 
segments of the market include soft drinks (primarily enhanced water and energy drinks) and 
dairy products, especially yogurts. Both consumer demand and the potential for premium pricing 
by manufacturers and retailers47 are attracting suppliers to this market. 
Some observers differentiate between major manufacturers of nutritional products, with 
significant investments in brand reputations, and smaller manufacturers, some of which operate 
on the fringe of legality.  Steve Mister, president of the Council for Responsible Nutrition, a 
trade association representing dietary supplement and functional food manufacturers, describes 
the supplement business as a “tale of two industries. There's a mainstream, responsible industry. 
Then there is this sort of shadow industry, the smaller guys playing around the fringes. The 
                                                                                                                                                             
http://www.marketwired.com/press-release/international-probiotics-functional-foods-dietary-supplements-specialty-
nutrients-animal-1926353.htm; Jane E. Brody, Putting Good Bacteria to Work, N.Y. TIMES (Sept. 14, 2004), 
http://www.nytimes.com/2004/09/14/health/14brod.html; supra note 12. 
45 Multinationals in the functional food market include PepsiCo, Coca-Cola, General Mills, Kellogg, Kraft, Nestle, 
Danone, Unilever and Yakult. See PRICE WATERHOUSE COOPERS, supra note 43, at 8. 
46 PRICE WATERHOUSE COOPERS, supra note 43, at 5. 
47 See id. at 10 (stating that “[a]lthough these products typically require greater initial R&D and ingredient costs, 
price premiums may reach 30 percent or higher, depending on the product”). 
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problem is how we distinguish between the two.”48 He characterizes some members of the 
industry as “rogue players” who “are poisoning the reputation of the industry” for everyone.49  
 
III. REGULATION OF HEALTH CLAIMS AND RECENT EFFORTS TO COMBAT DECEPTIVE 
CLAIMS 
Federal statutes regulating deceptive health claims include the Food Drug and Cosmetic 
Act,50 the Dietary Supplement Health and Education Act,51 the Nutrition Labeling and Education 
Act,52 and the Federal Trade Commission Act.53 Each statute, augmented by agency regulations 
                                                 
48 Alison Young, Unmasking the People Behind Risky Pills: A USA Today Investigation, USA TODAY (Dec. 20, 
2013), http://www.usatoday.com/story/news/nation/2013/12/19/dietary-supplements-executives-criminal-records-
spiked/4114451/. 
49 Steve Mister, The Supplement Industry’s ‘Identity’ Crisis, NATURAL PRODUCTS INSIDER (Feb. 10, 2012), 
http://www.naturalproductsinsider.com/articles/2012/02/the-supplement-industry-s-identity-crisis.aspx (describing 
mislabeling and the use of substandard ingredients). 
50 Food, Drug, and Cosmetic Act of 1938, Pub. L. No. 75-717, 52 Stat. 1040 (codified at 21 U.S.C. §§ 301–399). 
51 Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, 108 Stat. 4332 (codified at 21 
U.S.C. §§ 301, 321, 342-343, 350(b) and 42 U.S.C. §287). 
52 Nutrition Labeling and Education Act (NLEA) of 1990, Pub. L. No. 101-535, 104 Stat. 2353 (codified at 21 
U.S.C. § 343). 
53 15 U.S.C. §§ 41-58 (2012). The Lanham Act also establishes a cause of action for false advertising. See 15 U.S.C. 
§ 1125(a) (2012). However, only those who allege an injury to commercial interests have standing to bring a 
Lanham Act false advertising claim; consumers do not. Lexmark Int’l, Inc. v. Static Control Components, Inc., 134 
S. Ct. 1377, 1390 (2014).  See also POM Wonderful LLC v. Coca-Cola Co., 134 S. Ct. 2228, 2234 (2014).  
Although consumers do not have a right of action under the Lanham Act, theories of Lanham Act liability and 
related burden of proof obligations may be pertinent to analysis of a state law based false advertising claim. See In 
re GNC Corp., 789 F.3d 505 (4th Cir. 2015).  
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and guidance documents, has a separate framework for establishing when claims violate the law. 
In addition to these federal laws, state consumer protection laws provide standards for making 
claims about consumer products and another enforcement avenue for consumers harmed by 
deceptive advertising.  
A. FDA 
 FDA is responsible for assuring that foods and dietary supplements are properly labeled 
and, if they make claims about the products, that such claims are not false or misleading.54 Food 
labeling is in large part governed by the Nutrition Labeling and Education Act (NLEA) of 1990, 
which requires most foods to include nutrition labeling and “requires food labels that bear 
nutrient content claims and certain health messages to comply with specific requirements.”55 In 
addition, under the FD&C Act, foods and dietary supplements may not be adulterated or 
misbranded.56 A product is misbranded if its label is “false or misleading in any particular”57 or 
it is not in compliance with labeling requirements.58  As to claims, FDA statutes and regulations 
permit manufacturers of foods and dietary supplements to make three types of claims on their 
labels: health, nutrient content, and structure/function claims.59 Foods and dietary supplements 
                                                 
54 21 U.S.C. §§ 331(a), 343(a) (2012). 
55 U.S. FOOD & DRUG ADMIN., A FOOD LABELING GUIDE (Jan. 2013), 
http://www.fda.gov/downloads/Food/GuidanceRegulation/UCM265446.pdf [hereinafter A FOOD LABELING GUIDE]. 
56 21 U.S.C. §§ 342-343 (2012). 
57 § 343(a)(1). 
58 § 343(a)(2). 
59 See Label Claims for Conventional Foods and Dietary Supplements, U.S. FOOD & DRUG ADMIN. (Dec. 2013), 
http://www.fda.gov/Food/IngredientsPackagingLabeling/LabelingNutrition/ucm111447.htm [hereinafter Label 
Claims].   
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may not make disease claims, which are claims that describe the effect of a substance on the 
diagnosis, treatment, mitigation, cure or prevention of disease.60  Any product that makes a 
disease claim is considered a drug and must go through the extensive and costly drug approval 
process prior to marketing.61  
Of the three types of claims permissible for dietary supplements and foods, only claims in the 
health claim category require premarket approval by FDA. These claims include “health claims” 
and “qualified health claims.”  Prior to 1990, health claims on food products were prohibited.  It 
was only after the passage of the NLEA62 that health claims were permitted.63  
FDA defines health claims as claims made on the label or in labeling of a food or dietary 
supplement that characterize the relationship between the labeled substance and reduced risk of a 
disease or health-related condition.64  Health claims for foods and dietary supplements may be 
approved by FDA if there is “significant scientific agreement” that the claimed relationship 
between the nutritional product and reduction of risk of disease is true. FDA responds to a 
petition for approval and authorizes these types of health claims based on an extensive review of 
the scientific literature and by promulgation of a specific regulation permitting the claim.65 An 
                                                 
60 See § 321(g)(1).  
61 See Development & Approval Process (Drugs), U.S. FOOD & DRUG ADMIN. (Oct. 27, 2014), 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ (describing the drug approval process). 
62 Nutrition Labeling and Education Act of 1990, Pub. L. No. 101-535, 104 Stat. 2353 (codified at 21 U.S.C. § 343).  
63 Id. See also Constance J. Geiger, Health Claims: History, Current Regulatory Status, and Consumer Research, 98 
J. AM. DIETETIC ASS’N 1312 (1998). 
64 U.S. FOOD & DRUG ADMIN., A FOOD LABELING GUIDE, supra note 55, at 80. 
65 See Label Claims, supra note 59. This mechanism of approval for health claims was established by the Nutrition 
Labeling and Education Act of 1990. Id. 
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example of a health claim approved under this process is “adequate calcium throughout life, as 
part of a well-balanced diet, may reduce the risk of osteoporosis”.66  
Under the Food and Drug Administration Modernization Act of 1997 (FDAMA), 
manufacturers may also make health claims for foods (but not dietary supplements) if the health 
claim is based on an “‘authoritative statement’ from a scientific body of the U.S. Government67 
or the National Academy of Sciences.”68 A food manufacturer or distributor that intends to make 
such a claim must submit a notification to FDA, which has 120 days to respond if it finds that the 
notification does not comply with FDAMA.69 Marketing under this route does not require 
promulgation of a regulation; however, FDA may prohibit or modify such a claim by 
regulation.70  
                                                 
66 Health Claims: Calcium, Vitamin D, and Osteoporosis, 21 C.F.R. § 101.72(e) (2014). 
67 Label Claims, supra note 59. FDAMA specifically lists the National Institutes of Health (NIH) and the Centers for 
Disease Control and Prevention (CDC) as scientific bodies that would satisfy the statutory requirement. 21 U.S.C. 
§ 343(r)(2)(G)(i) (2012). FDA has also stated that the Surgeon General within the Department of Health and Human 
Services, the Food and Nutrition Service, the Food Safety and Inspection Service, and the Agricultural Research 
Service within the Department of Agriculture, may serve as qualified “scientific bodies.”  See Guidance for 
Industry: Notification of a Health Claim or Nutrient Content Claim Based on an Authoritative Statement of a 
Scientific Body, U.S. FOOD & DRUG ADMIN. (July 11, 1998), 
http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/LabelingNutrition/ucm0
56975.htm [hereinafter Notification of a Health Claim].  
68 Label Claims, supra note 59.  
69 In such case, the submitter may revise the notification and resubmit it. The food may not be marketed with the 




An additional type of health claim, the “qualified health claim” (QHC), was established by 
FDA in response to a court’s decision that a dietary supplement manufacturer has a First 
Amendment right to make health claims based on less scientific evidence than the standard of 
“significant scientific agreement,” as long as such claims do not mislead consumers. 71  QHCs 
can be made for both foods and dietary supplements and differ from other health claims in that 
they must include a disclaimer or be otherwise qualified.72  Manufacturers or distributors 
wishing to make a QHC must submit a petition to FDA summarizing the scientific data in 
support of the claim the petitioner wishes to make, including copies of computer literature 
searches, all research articles relied upon for support of the petition, and information about any 
adverse consequences from the food or dietary supplement for any segment of the U.S. 
population.73 
                                                 
71 See Pearson v. Shalala, 164 F.3d 650 (D.C. Cir. 1999). In Pearson, the plaintiffs (dietary supplement 
manufacturers) challenged FDA’s health claim regulations for dietary supplements and the agency’s decision not to 
approve health claims for four specific substance/disease relationships. The U.S. Court of Appeals for the D.C. 
Circuit held that the First Amendment does not permit the FDA to reject health claims that the agency determines to 
be potentially misleading, unless the agency also reasonably determines that no disclaimer would eliminate the 
potential deception. Id.  
72 An example of a QHC is: “One small study suggests that chromium picolinate may reduce the risk of insulin 
resistance. . . FDA concludes, however, that the existence of such a relationship . . . is highly uncertain.”  Qualified 
Health Claims: Letter of Enforcement Discretion – Chromium Picolinate and Insulin Resistance (Docket No. 
2004Q-0144), U.S. FOOD & DRUG ADMIN. (Aug. 25, 2005), 
http://www.fda.gov/Food/IngredientsPackagingLabeling/LabelingNutrition/ucm073017.htm.  
73 See A FOOD LABELING GUIDE, supra note 55, at 83.  This guidance document states:  
Within 15 days of receipt, FDA will acknowledge the petition. Within 45 days of receipt, FDA 
will file the petition and a docket number will be assigned. . . . At the time of filing, FDA will post 
the petition on the FDA webpage for a 60-day public comment period. During this time, written 
comments may be submitted to the docket. On or before 270 days after receipt of the petition, a 
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Food manufacturers may make a second type of claim, “nutrient content claims.” Subject to 
FDA’s criteria,74 a manufacturer may make claims, for example, that a product is good, 
excellent, enriched/fortified or high potency with respect to vitamins, minerals, fiber, or protein; 
that a product is “lite” or “light” with regard to calories or sodium; or even that a product is 
“healthy.”75 Such claims can be used on labels without review by FDA, as long as they comply 
with all FDA definitions and rules.76  All other nutrient content claims are prohibited.77 
Foods and dietary supplement manufacturers can also make structure/function claims,78 
which are claims that describe the role of a nutrient or dietary ingredient intended to affect the 
normal structure or functions of the body in humans.79 Although there is no premarket approval 
                                                                                                                                                             
final decision will be sent to the petitioner in the form of a letter as to whether FDA intends to 
exercise enforcement discretion with respect to a QHC or deny the petition. The letter will be 
posted on FDA’s website. Extensions beyond 270 days can be granted upon mutual agreement 
between the petitioner and the agency.  
Id. 
74 Id. at 87. 
75 Id. at 91–94. Historically the claim “healthy” “has received special scrutiny and guidelines from the FDA because 
“[it] is a very useful advertising term. According to FDA guidelines, a product must have low total fat content as 
well as low levels of saturated fat, sodium, and cholesterol to qualify as a ‘healthy’ food.”  Betty J. Parker, Food for 
Health-The Use of Nutrient Content, Health, and Structure/function Claims in Food Advertisements, J. 
ADVERTISING, Fall 2003, at 47, 48–49. See also 21 C.F.R. § 101.65(d)(2) (2014). 
76 FDA deems a food misbranded if it bears a nutrient content claim unless the agency has issued a regulation 
authorizing the claim and the claim is made consistent with the regulation. 21 U.S.C. § 343(r)(6) (2012). 
77 U.S. FOOD & DRUG ADMIN., A FOOD LABELING GUIDE, supra note 55, at 72 (citing 21 C.F.R. § 101.13(b)).  
78 Along with structure/function claims, the Dietary Supplement Health and Education Act of 1994 (DSHEA) also 
permits general well-being and nutrient deficiency disease claims for dietary supplements. Neither of these claims is 
subject to premarket approval. See Label Claims, supra note 59. 
79 STRUCTURE/FUNCTION CLAIMS FAIL, supra note 9, at 4 (“For example, a supplement may claim that it ‘curbs 
appetite to help with weight loss,’ but it may not claim to ‘aid weight loss to treat obesity’ because obesity is a 
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for these claims, the manufacturer is responsible for ensuring their truthfulness and for having 
substantiation to support the claims.80 For dietary supplements (but not foods) making 
structure/function claims, the manufacturer must notify FDA within 30 days of placing the 
product on the market. The notification must include an attestation by the manufacturer that the 
“[manufacturer] has substantiation that the claim is truthful and not misleading.”81 In addition, 
dietary supplement manufacturers making structure/function claims must include a disclaimer 
that the claim has not been evaluated by FDA and that the product is “not intended to ‘diagnose, 
treat, cure or prevent any disease.’”82 
Of each of the three types of claims that nutritional product manufacturers may make, 
structure/function claims are especially problematic in terms of consumer deception. The fact 
that these claims do not require premarket approval creates at least the opportunity for claims 
                                                                                                                                                             
disease. Similarly, a supplement may claim to ‘support immunity,’ but may not claim to ‘boost the immune system 
against colds and flu’ because the latter references specific diseases.”).  
80 See id. FDA has set forth guidance on what types of evidence can be used for claim substantiation. See Guidance 
for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r)(6) of the Federal Food, 
Drug and Cosmetic Act, U.S. FOOD & DRUG ADMIN. (Dec. 2008), 
http://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/dietarysupplements/ucm073
200.htm. To meet the substantiation requirement, evidence must be “competent and reliable scientific evidence.” Id. 
In determining whether the standard is met, FDA considers: “(1) the meaning of the claim(s) being made;  (2) the 
relationship of the evidence to the claim; (3) the quality of the evidence [e.g., randomized controlled trials are given 
considerable weight although manufacturers may use other human or nonhuman studies]; and (4) the totality of the 
evidence [both favorable and unfavorable.]”  Id.  
81 STRUCTURE/FUNCTION CLAIMS FAIL, supra note 9, at 6 (citing 21 C.F.R. § 101.93(a)(2) (2014)). 
82 Label Claims, supra note 59. 
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that lack scientific support and even outright false statements.83  Structure/function claims are 
also used much more frequently than health claims apparently because they allow companies to 
bypass the approval process required for health claims.84 The OIG and GAO have issued several 
reports critical of structure/function claims, especially as they relate to dietary supplements.85   
B. FTC 
The FTC’s requirements regarding substantiation for health related product claims differ 
from those of FDA. Unlike FDA, the FTC does not require pre-market approval of claims, nor 
does it make regulatory distinctions between product categories (e.g., drug, supplement, food), 
nor between types of claims (e.g., health, nutrient content, structure/function).86  However, the 
FTC has legal authority to take action against false or misleading claims for many types of 
products and services. These include foods, drugs, and dietary supplements.87   
                                                 
83 See CSPI REPORTS: INT’L, Marketplace Implications and Consumer Impact, in FUNCTIONAL FOODS: PUBLIC 
HEALTH BOON OR 21ST CENTURY QUACKERY? (1998), https://cspinet.org/reports/functional_foods/usa_market.html.  
84 See Parker, supra note 75, at 49. See also CSPI REPORTS INT’L, supra note 83 (stating that “[t]o avoid FDA 
approval requirements, some companies have begun making structure/function claims in lieu of health claims.”).  
85 STRUCTURE/FUNCTION CLAIMS FAIL, supra note 9; OFFICE OF INSPECTOR GEN., U.S. DEP’T OF HEALTH & HUMAN 
SERVICES, DIETARY SUPPLEMENT LABELS: AN ASSESSMENT (Mar. 2003), https://oig.hhs.gov/oei/reports/oei-01-01-
00121.pdf; Testimony of Gregory D. Kutz, supra note 9; U.S. GOV’T ACCOUNTABILITY OFFICE,GAO-09-250, 
REPORT TO CONGRESSIONAL REQUESTERS: DIETARY SUPPLEMENTS: FDA SHOULD TAKE FURTHER ACTIONS TO 
IMPROVE OVERSIGHT AND CONSUMER UNDERSTANDING (Jan. 2009), http://www.gao.gov/assets/290/285372.pdf. 
86 Michelle Rusk, Att’y, U.S. Fed. Trade Comm’n, Div. of Advertising Practices, Staff Presentation at the Inst. of 
Medicine Food Forum Workshop: Health Claims and FTC Advertising Law (Feb. 23, 2012), 
http://iom.nationalacademies.org/~/media/1EBC076FE7CC4AC0BB922166367899FC.ashx. 
87 See Anne V. Maher, Marketing Dietary Supplements and Functional Foods in the USA: The Federal Trade 
Commission’s Advertising Substantiation Requirements, in NUTRACEUTICAL AND FUNCTIONAL FOOD REGULATIONS 
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The FTC’s jurisdiction over health claims stems from three provisions of the FTC Act. 
Section 5 of the Act prohibits “unfair or deceptive acts or practices in or affecting commerce.”88 
Section 12 prohibits false advertisements for foods, drugs, devices, services, or cosmetics,89 and 
Section 15 defines false advertisement for the purpose of section 12 as one that is “misleading in 
a material respect.”90 In a separate policy statement, FTC has explained that in its enforcement of 
these provisions it looks to whether the claim contains a misrepresentation or omission of fact 
that is likely to mislead a consumer acting reasonably under the circumstances, and whether that 
representation is material to a consumer’s purchasing decision.91 Thus false claims, claims made 
without disclosure of material facts, or unsubstantiated claims may all violate the law.  
The FTC interprets ads from the perspective of a reasonable consumer in the target 
audience.92 For some advertising, this audience is the general population. If, however, a 
manufacturer targets its product to a particular subgroup, the ad will be evaluated from the 
perspective of how it is likely to be interpreted by a reasonable member of that group.93 
Although ads may have more than one reasonable interpretation, where an ad conveys more than 
one meaning, only one of which is misleading, a seller is liable for the misleading interpretation 
                                                                                                                                                             
IN THE UNITED STATES AND AROUND THE WORLD 47, 48 (Debasis Bagchi ed., 2008), (stating that the FTC “has 
authority to take legal action against false and misleading claims for nearly every type of product and service, 
including products which are also regulated by the . . . FDA, such as dietary supplements and functional foods.”).  
88 15 U.S.C. § 45(a)(1) (2012). 
89 § 52.  
90 § 55(a)(1). 
91 FTC Policy Statement on Deception, U.S. FED. TRADE COMM’N (Oct. 14, 1983), https://www.ftc.gov/public-
statements/1983/10/ftc-policy-statement-deception. 




even if non-misleading interpretations are possible.94 Consumers may be especially susceptible 
to health claims, because they usually lack the knowledge to assess claims referring to 
physiology or metabolic processes and may be especially impressed by purported scientific 
evidence bolstering the claims.95  
In the FTC’s long-held view, making claims without a reasonable basis is a deceptive 
practice. In determining whether there is a “reasonable basis” for a claim, the FTC will consider: 
“the type of claim, the product, the consequences of a false claim, the benefits of a truthful claim, 
the cost of developing substantiation for the claim, and the amount of substantiation experts in 
the field believe is reasonable.”96 Where an advertisement represents, either expressly or by 
implication, that the claim is supported by a certain amount or level of substantiation, the 
advertiser must possess, at the time the claim is made, at least that level of support for the 
claim.97 
                                                 
94 Id. 
95 For example, POM Wonderful, the marketer of pomegranate juice products claimed to have various health 
benefits, “thought their products [sic] impact on health was such a strong selling point that they invested over $35 
million to develop supporting evidence that they could use in marketing.” In re POM Wonderful LLC, 155 F.T.C. 1, 
42 (2013). 
96 FTC Policy Statement Regarding Advertising Substantiation, U.S. FED. TRADE COMM’N (Mar. 11, 1983), 
https://www.ftc.gov/public-statements/1983/03/ftc-policy-statement-regarding-advertising-substantiation; see also 
DIETARY SUPPLEMENTS: AN ADVERTISING GUIDE FOR INDUSTRY 8–9 (2001), 
https://www.ftc.gov/system/files/documents/plain-language/bus09-dietary-supplements-advertising-guide-
industry.pdf ; see also In re Pfizer Inc., 81 F.T.C. 23 (1972). 
97 FTC Policy Statement Regarding Advertising Substantiation, supra note 96. See also Enforcement Policy 
Statement on Food Advertising, U.S. FED. TRADE COMM’N (May 13, 1994), https://www.ftc.gov/public-
statements/1994/05/enforcement-policy-statement-food-advertising [hereinafter Food Policy Statement].  FTC’s 
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Although the FTC does not have separate rules governing foods and dietary supplements, it 
has issued industry guidance documents for both products.98 The Commission’s Enforcement 
Policy Statement on Food Advertising was made public in May 1994. This was prior to the 
passage of DSHEA, which as discussed above, allows dietary supplement manufacturers to make 
structure/function claims without FDA approval prior to marketing. As a result, the statement 
focuses on health claims and nutrient content claims. The subsequent passage of DSHEA raised 
numerous questions about the FTC’s approach to applying its consumer protection laws to 
dietary supplements. The guidance document for dietary supplement manufacturers states that 
the FTC’s “approach to supplement advertising is best illustrated by its Enforcement Policy 
Statement on Food Advertising” and that in general the FTC gives “great deference to an FDA 
determination of whether there is adequate support for a health claim.”99 
Both guidance documents provide that health-related claims must be substantiated by 
competent and reliable scientific evidence.100 More specifically, this is evidence consisting of 
tests, analyses, research, studies or other evidence based on the expertise of 
professionals in the relevant area, conducted and evaluated in an objective manner 
                                                                                                                                                             
Bureau of Consumer Protection website on “Health Claims” states that “Companies must support their advertising 
claims with solid proof. This is especially true for businesses that market food, over-the-counter drugs, dietary 
supplements, contact lenses, and other health-related products.” Health Claims, U.S. FED. TRADE COMM’N, 
http://business.ftc.gov/advertising-and-marketing/health-claims. 
98 See Food Policy Statement, supra note 97; see DIETARY SUPPLEMENTS: AN ADVERTISING GUIDE FOR INDUSTRY, 
supra note 96. 
99 DIETARY SUPPLEMENTS: AN ADVERTISING GUIDE FOR INDUSTRY, supra note 96, at 1. 
100 Id. at 9; Enforcement Policy Statement on Food Advertising, supra note 97. 
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by persons qualified to do so, using procedures generally accepted in the 
profession to yield accurate and reliable results.101  
In evaluating health claims for foods and dietary supplements the FTC will look to “well-
designed studies, including clinical research and other forms of reliable and probative scientific 
evidence.”102 Furthermore, the FTC states that it will apply the same “significant scientific 
agreement” standard applied by FDA to claims “about the relationship between a nutrient or 
substance in a food and a disease or health-related condition.”103 
In evaluating a structure/function claim for a dietary supplement, the FTC will assess 
whether the claim may convey an implied claim that the product will treat a disease. If so, the 
manufacturer will need to provide substantiation of the implied disease treatment claim.104 The 
industry guidance document for dietary supplements states that for substantiation there “is no 
fixed formula for the number or type of studies required or for more specific parameters like 
sample size and study duration. There are, however, a number of considerations to guide an 
advertiser in assessing the adequacy of the scientific support for a specific advertising claim.”105 
These include whether the advertiser has the level of support it claims to have; whether experts 
                                                 
101 DIETARY SUPPLEMENTS: AN ADVERTISING GUIDE FOR INDUSTRY, supra note 96, at 9; Enforcement Policy 
Statement on Food Advertising, supra note 97. 
102 Enforcement Policy Statement on Food Advertising, supra note 97. 
103 Id. 
104 The FTC industry guidance document on advertising dietary supplements provides an example of this:  
An ad for a dietary supplement called ‘Arthricure’ claims that the product maintains joint health 
and mobility into old age. The ‘before’ picture shows an elderly woman using a walker. The 
‘after’ picture shows her dancing with her husband. The images and product name likely convey 
implied claims that the product is effective in the treatment of the symptoms of arthritis, and may 
also imply that the product can cure or mitigate the disease. The advertiser must be able to 
substantiate these implied claims. 
DIETARY SUPPLEMENTS: AN ADVERTISING GUIDE FOR INDUSTRY, supra note 96, at 5.  
105 Id. at 9. 
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in the relevant area of study would generally agree that the amount and type of evidence for the 
particular claim is sufficient; whether any research conducted was well designed, implemented 
and analyzed; whether the totality of the evidence supports the claim; and whether the evidence 
is relevant to the specific claim.106  
Although FDA regulates labeling, the FTC will also evaluate dietary supplement labels if 
they are being used by an advertiser to promote the product and will follow an approach similar 
to FDA’s review of such materials in the context of labeling.107   
 
C. Recent Enforcement Efforts  by FDA and the FTC Against Nutritional Product 
Manufacturers for Deceptive Claims 
Under a memorandum of understanding (MOU) originally executed in 1954, FDA and the 
FTC share jurisdiction for enforcement of claims made by manufacturers of health-related 
products.108 The FDA has primary authority for overseeing the advertising of prescription drugs 
and the labeling109 of drugs, supplements, foods, devices and cosmetics. With the exception of 
                                                 
106 Id. at 9–18. 
107 Id. at 24.  
108 The allocation of responsibility for enforcement of food and dietary supplement labels and claims is set forth in a 
memorandum of understanding between the two agencies. See  Memorandum of Understanding Between the Federal 
Trade Commission and The Food and Drug Administration (1971), MOU 225-71-
8003,http://www.fda.gov/AboutFDA/PartnershipsCollaborations/MemorandaofUnderstandingMOUs/DomesticMO
Us/ucm115791.htm. 
109 Labeling is interpreted broadly to include “visual, audio or other material that bears a strong contextual 
relationship to the product.” John E. Villafranco & Andrew B. Lustigman, Regulation of Dietary Supplement 
Advertising: Current Claims of Interest to the Federal Trade Commission and National Advertising Division, 62 
FOOD & DRUG L.J. 709, 711 (2007) (citing 21 U.S.C. § 321(m) and Kordel v. United States, 335 U.S. 345 (1948)). 
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prescription drugs, the FTC has primary authority for overseeing advertising of health-related 
products. The MOU did not address claims made on the Internet, but “both agencies have 
asserted jurisdiction over claims appearing on company websites.”110 The agencies coordinate 
closely on food and dietary supplement policy issues.111 
FDA and the FTC have a variety of enforcement tools available to address deceptive claims. 
For example, FDA can ask companies to voluntarily recall any product that has already entered 
the distribution chain.112 In addition, FDA can send a warning letter to a firm stating that 
enforcement actions may be forthcoming if corrections are not made.113 If violations are not 
                                                 
110 Maher, supra note 87, at 48. 
111 See John E. Villafranco, Raqiyyah R. Pippins, & Kristi L. Wolff, Working Together: How Growing FDA And 
FTC Collaboration Changes the Regulatory Landscape for Food and Dietary Supplement Marketers, NUTRITION 
OUTLOOK (May 2011), 
http://www.kelleydrye.com/publications/articles/1485/_res/id=Files/index=0/Villafranco_Pippins_Wolff_Working%
20Together_Nutritional%20Outlook_%20May%202011.pdf (“Early in the Obama Administration, the FDA and 
FTC expressed a commitment to interagency collaboration in regulating the promotion of food, beverage, and 
dietary supplement products, and established ‘working groups’ to share information regarding marketing activities 
for such products.”).  See also Sarah Roller & Raquiyyah Pippins, Marketing Nutrition & Health-Related Benefits of 
Food & Beverage Products: Enforcement, Litigation & Liability Issues, 65 FOOD & DRUG L.J. 447 (2010). 
112 See 21 CFR §§ 7.40-7.42, 7.45 (2014).  
113 See U.S. FOOD & DRUG ADMIN., Warning Letters, in REGULATORY PROCEDURES MANUAL, 




corrected, FDA can seize and remove the product from the marketplace.114 Both FDA and the 
FTC can enjoin a firm from continuing a practice that violates labeling or advertising statutes 
and regulations, i.e., seek an injunction115 or cease and desist order. In addition, the FDA can 
recommend criminal prosecution of a company engaging in criminal conduct,116 and the FTC 
can assess civil monetary penalties, order refunds to consumers, and require corrective 
advertising, disclosures, and other informational remedies aimed at rectifying the deception.117 
During the mid-2000s, FDA was criticized by public interest groups, Congress and the GAO 
for its inability to keep up with the prevalence of food labeling violations by taking necessary 
enforcement actions.118  CSPI pointed out the small number of warning letters issued by the 
                                                 
114 See U.S. FOOD & DRUG ADMIN., Seizure, in REGULATORY PROCEDURES MANUAL, 
http://www.fda.gov/ICECI/ComplianceManuals/RegulatoryProceduresManual/ucm176733.htm (last visited Aug. 
19, 2015). 
115 U.S. FOOD & DRUG ADMIN., Injunctions, in REGULATORY PROCEDURES MANUAL, 
http://www.fda.gov/ICECI/ComplianceManuals/RegulatoryProceduresManual/ucm176734.htm (last visited Aug. 
19, 2015).  
116 See 21 U.S.C. § 333(a)(1) (2012); U.S. FOOD & DRUG ADMIN., Prosecution, in REGULATORY PROCEDURES 
MANUAL,  http://www.fda.gov/ICECI/ComplianceManuals/RegulatoryProceduresManual/ucm176738.htm (last 
visited Aug. 19, 2015); see also John W. Lundquist & Sandra L. Conroy, Defending Against Food & Drug 
Prosecutions, THE CHAMPION (July 1997), http://www.nacdl.org/CHAMPION/ARTICLES/97jul02.htm. While the 
law allows for civil monetary penalties against drug and medical device manufacturers it does not provide for civil 
penalties for violations by food and dietary supplement manufacturers. See 21 U.S.C. § 335b (2012). 
117 Advertising FAQ’s: A Guide for Small Business, U.S. FED. TRADE COMM’N (Apr. 2001), 
https://www.ftc.gov/tips-advice/business-center/guidance/advertising-faqs-guide-small-business.  
118 See Nicole Negowetti, Food Labeling Litigation: Exposing Gaps in the FDA’s Resources and Regulatory 




agency in light of the apparent growing numbers of labels that did not comply with the law and 
asserted that FDA had “all but abdicated its responsibility to police inaccurate nutrition 
statements and misleading health-related claims on food labels.”119 In 2009 and 2010, FDA 
issued two open letters to the food industry urging manufacturers to comply with labeling 
requirements and in 2010, as part of an enforcement initiative, issued seventeen Warning Letters 
in one day to food manufacturers that were alleged to have made unsubstantiated or misleading 
health and nutrient content claims.120 From January 2011 to June 2012, FDA issued “numerous 
warning letters” to food manufacturers for failure to comply with requirements for food labeling 
and health claims.121 Since June 2012, FDA has continued to issue warning letters at the rate of 
about sixty per year122 to food and dietary supplement manufacturers whose labels or claims 
                                                                                                                                                             
labeling-litigation.pdf (citing Center for Science in the Public Interest, Rebuttal to FDA Report to Congress on 
Agency Enforcement Actions Regarding Health-Related Claims on Food Labels (July 18, 2006), 
http://cspinet.org/new/pdf/fn5rep.pdf [hereinafter Rebuttal to FDA Report]; S. REP. NO. 109-92, at 153 (2005); H.R. 
REP. NO. 109-102, at 83 (2005); and U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-08-597, FOOD LABELING: FDA 
NEEDS TO BETTER LEVERAGE RESOURCES, IMPROVE OVERSIGHT AND EFFECTIVELY USE AVAILABLE DATA TO HELP 
CONSUMERS SELECT HEALTHY FOODS (Sept. 2008), http://www.gao.gov/new.items/do8597.pdf).  
119 Negowetti, supra note 118 (quoting Rebuttal to FDA Report). 
120 Id.  See also ABA Section of Litigation, Food & Supplements Second Annual Workshop, Food Labeling: How to 
Avoid an FDA or FTC Enforcement Action 3 (June 12, 2012), 
http://www.americanbar.org/content/dam/aba/administrative/litigation/materials/2012_food_supplements_2nd_annu
al_cle_wrkshp/2012_aba_panel3_food_labeling_how_to_avoid_an_fda_or_ftc_enforcement_action.authcheckdam.p
df; Summary of 17 Warning Letters Issued by FDA on February 22, 2010 for Alleged Food Labeling Violations, 
KELLER AND HECKMAN LLP (Feb. 22, 2010), http://www.khlaw.com/3640.  
121 ABA Section of Litigation, supra note 120.  
122 See Warning Letters, U.S. FOOD & DRUG ADMIN. (2015), 
http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/default.htm; see also 2014 Year-End FDA 
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violate the law but has not generally engaged in other methods of enforcement against these 
companies.123 Moreover, FDA has issued very few warning letters for certain types of claims, 
specifically qualified health claims.  According to a recent article, the “FDA has issued only 
seven warning letters referencing qualified health claims” and has stated that “promotional 
health-related claims are not a high enforcement priority.”124 
 The FTC has been somewhat more active in enforcement of laws under its jurisdiction 
regarding deceptive health claims.125   In a prepared statement given to the Senate Special 
Committee on Aging as part of a hearing on deceptive marketing of dietary supplements in 2010, 
the FTC stated that over the past decade (2000-2010) it had filed “well over 100 law enforcement 
actions challenging claims about the efficacy or safety of a wide variety of supplements”126 and 
                                                                                                                                                             
Compliance and Enforcement Update-Food and Dietary Supplements, GIBSON DUNN (Mar. 2, 2015), 
http://www.gibsondunn.com/publications/Documents/2014-Year-End-FDA-Compliance-and-Enforcement-Update-
Food-and-Dietary-Supplements.pdf (stating that in 2014 FDA issued 252 warning letters for conventional foods and 
58 for dietary supplements. The letters for foods primarily cited violations of current good manufacturing practices 
while those for dietary supplements were for what we have described as deceptive health claims, i.e., improperly 
marketing products as dietary supplements when those products were actually new drugs.)  
123 See Warning Letters, supra note 122.   
124 Peter E. Masaitis & Evan W. Woolley, Enforcement of FDA Qualified Health Claims: Who’s on the Case?, 
INSIDE COUNSEL MAGAZINE (Jan. 9, 2015), http://www.insidecounsel.com/2015/01/09/enforcement-of-fda-
qualified-health-claims-whos-on. 
125 See ABA Section of Litigation, supra note 120. 
126 Deceptive Marketing of Dietary Supplements: FTC Enforcement Activities, U.S. FED. TRADE COMM’N 4 (May 
26, 2010), https://www.ftc.gov/sites/default/files/documents/public_statements/prepared-statement-federal-trade-
commission-deceptive-marketing-dietary-supplements/100526dietarysupplementstatement.pdf (statement prepared 
for Senate Special Committee on Aging hearing). See also Health and Fitness Claims, supra note 36 (stating that 
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that it “focused its enforcement on national advertising campaigns for products with unproven 
benefits, products promoted to treat or cure serious diseases, products that may present 
significant safety concerns to consumers, and products that are deceptively marketed to 
vulnerable populations, such as children or the elderly.”127 Recent examples of major FTC 
enforcement actions include cases against Nestlé Healthcare Nutrition, Inc. (a subsidiary of 
Nestlé S.A.), the Dannon Company, and POM Wonderful, LLC.  
In 2010, the FTC brought an action against Nestlé Healthcare Nutrition, Inc. for claims made 
about its product, Boost Kid Essentials.128 The product is a nutritional drink for children with 
probiotics embedded in a straw that comes with the drink. Advertisements for the product 
claimed that consumption of the drink would reduce illness in children, protect children from 
colds and flu by strengthening their immune system, and help children up to age thirteen recover 
more quickly from diarrhea.  The FTC alleged in a complaint brought against the manufacturer 
that these claims were unsubstantiated and thus violated the FTC Act. This was the agency’s first 
complaint challenging deceptive advertising of a probiotic product. In response, the company 
agreed as part of a settlement to stop claiming that BOOST Kid Essentials would (1) reduce the 
risk of colds, flu, and other upper respiratory tract infections unless the FDA approved the 
claim129 and (2) “reduce children’s sick-day absences and the duration of acute diarrhea in 
                                                                                                                                                             
“over the last decade, the FTC has filed one hundred and twenty cases challenging health claims made for 
supplements.”). 
127 Deceptive Marketing of Dietary Supplements, supra note 126. 
128 In re Nestlé Healthcare Nutrition, Inc., Complaint filed by the U.S. Federal Trade Commission (2010), 
https://www.ftc.gov/sites/default/files/documents/cases/2010/07/100714nestlecmpt.pdf. 
129 FTC Approves Final Order Settling Charges That Nestlé Subsidiary Made Deceptive Health Claims for BOOST 
Kid Essentials, U.S. FED. TRADE COMM’N (Jan. 18, 2011), https://www.ftc.gov/news-events/press-
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children up to age 13, unless the claims [were] true and backed by at least two well-designed 
human clinical studies.”130 
In a second action in 2010, the FTC entered into a settlement with the Dannon Company, Inc. 
after alleging in a complaint that the company had engaged in deceptive advertising by 
exaggerating the health benefits of its Activia yogurt and DanActive dairy drink.131 In its 
complaint the FTC stated that “Dannon claimed in nationwide advertising campaigns that 
DanActive helps prevent colds and flu, and that one daily serving of Activia relieves temporary 
irregularity and helps with ‘slow transit time’” without sufficient evidence to back these 
claims.132 Similar to the settlement with BOOST Kid Essentials, the FTC required that Dannon 
refrain from claiming that “any yogurt, dairy drink, or probiotic food or drink reduces the 
                                                                                                                                                             
releases/2011/01/ftc-approves-final-order-settling-charges-nestle-subsidiary-made.  The FTC further required that 
the regulation be based on a finding that “there is significant scientific agreement among experts qualified by 
scientific training and experience to evaluate such claims, considering the totality of publicly available scientific 
evidence.” Nestlé HealthCare Nutrition, Inc.; Analysis of Proposed Consent Order to Aid Public Comment, 75 Fed. 
Reg. 42,752, 42,753 (July 22, 2010).  
130 FTC Approves Final Order, supra note 129.  The settlement also prohibits Nestlé HCN “from making any claims 
about the health benefits, performance, or efficacy of any probiotic and nutrition drinks that it sells at retail, unless 
the claims are true and backed by competent and reliable scientific evidence” and “from misrepresenting any tests or 
studies.” Id. 
131 See In re The Dannon Company, Inc. Agreement Containing Consent Order (2010), 
https://www.ftc.gov/sites/default/files/documents/cases/2010/12/101215dannonagree.pdf. 
132 Press Release, U.S. Fed. Trade Comm’n, Dannon Agrees to Drop Exaggerated Health Claims for Activia Yogurt 




likelihood of getting a cold or the flu, unless the claim is approved by the Food and Drug 
Administration.”133  
Another enforcement action involved the pomegranate juice products marketed by POM 
Wonderful. On September 24, 2010, the FTC issued an administrative complaint alleging that 
POM Wonderful engaged in deceptive acts and practices and disseminated false advertising in 
violation of Sections 5(a) and 12 of the FTC Act, through the marketing of its juice and related 
products.134  On review of an administrative law judge’s initial decision, the FTC found that 
POM Wonderful had made deceptive claims in thirty-six advertisements.135 The FTC held that 
POM Wonderful, without adequate substantiation, had made disease efficacy claims—namely, 
that its products could treat, prevent, or reduce the risk of heart disease, prostate cancer, and 
erectile dysfunction and that they were clinically proven to work.136 For example, several ads 
claimed that “eight ounces of POM a day can reduce plaque in the arteries by up to 30%!” The 
FTC wrote that “[s]uch references tend to communicate that the product’s attributes are 
supported by scientific research because a reduction in the amount of plaque in an individual’s 
                                                 
133  Id.  Prior to this action by the FTC, in 2009 the Dannon Co. settled a false advertising lawsuit regarding these 
products brought by private plaintiffs. See Timothy Williams, Dannon Settles With F.T.C. Over Some Health 
Claims, N.Y. TIMES (Dec. 15, 2010), http://www.nytimes.com/2010/12/16/business/16yogurt.html; see also infra 
notes 161-163 and accompanying text.   
134 Complaint at 19, In re POM Wonderful LLC, 155 F.T.C. 1 (Sept. 24, 2010) (No. 9344), 
http://www.ftc.gov/sites/default/files/documents/cases/2010/09/100927admincmplt.pdf.  
135 In re POM Wonderful LLC, 155 F.T.C. 1, 9 (2013). 
136 Id. at 38. 
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arteries cannot be known through casual observation, i.e., it must be measured by a medical 
professional.”137 
The FTC prohibited POM Wonderful from making disease-related efficacy claims unless the 
claims are supported by “competent and reliable scientific evidence,” which the FTC defined as 
at least two clinical trials that are “randomized, well controlled, based on valid end points, and 
conducted by persons qualified by training and experience to conduct such studies.” The agency 
further required that the studies “yield statistically significant results, and . . . be double-blinded 
unless [POM Wonderful could] demonstrate that blinding [could not] be effectively implemented 
given the nature of the intervention.”138 POM Wonderful appealed the FTC’s order, arguing that 
the FTC erred in its findings, imposed an unlawful remedy by requiring two randomized clinical 
trials, and transgressed First Amendment protection of commercial speech. The D.C. Circuit, 
however, largely rejected POM Wonderful’s contentions, holding that the FTC had substantial 
evidence in support of its findings and that POM Wonderful’s claims were not entitled to First 
Amendment protection.139  One modification ordered by the appellate court related to the 
remedy: the FTC’s requirement for two clinical trials in support of disease-related claims was 
deemed unjustifiably rigid and hence a First Amendment violation; one high-quality trial might 
suffice to substantiate a claim. This modification is significant in that it pushes back on the 
                                                 
137 In re POM Wonderful LLC, 155 F.T.C. 1, app. A, at A1-A2 (2013), 
http://www.ftc.gov/sites/default/files/documents/cases/2013/01/130116pomappendixa.pdf.  
138 In re POM Wonderful LLC, 155 F.T.C. 1 (2013).  
139 POM Wonderful, LLC v. Fed. Trade Comm’n, 777 F.3d 478 (D.C. Cir. 2015). 
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agency’s efforts to harmonize its regulation of health claims with FDA, in particular its 
substantiation requirement.140 
The FTC has continued to bring high-profile enforcement actions against other foods and 
dietary supplement manufacturers over the past few years. According to the 2014 Year-End FDA 
Compliance and Enforcement Update on food and dietary supplements, prepared by the law firm 
Gibson Dunn, in 2014 the FTC “stepped up its scrutiny of health-related claims,” in particular 
for weight loss products, and announced that deceptive health claims remained “an ongoing FTC 
priority with respect to deceptive advertising practices.”141  
D. State Consumer Protection Laws 
Most states have what are commonly “referred to as ‘mini-FTC’ Acts or UDAP (Unfair 
or Deceptive Acts or Practices) laws.”142 While these laws vary across states, most state UDAP 
laws provide state attorneys general with a broad array of remedies to combat consumer fraud 
and deception. UDAP statutes have also been used by private litigants in class action suits for 
alleged unfair and deceptive business practices.143  
                                                 
140 See Villafranco, Pippins, & Wolff, supra note 111. See also Douglas W. Hyman, The Regulation of Health 
Claims in Food Advertising: Have the FTC and the FDA Finally Reached a Common Ground?, 51 FOOD & DRUG 
L.J. 191 (1996). 
141 GIBSON DUNN, supra note 122. During the year the agency entered into “multiple weight-loss product 
settlements, most of which required the defendants to substantiate any future weight-loss claims with at least two 
adequate and well-controlled human studies.” Id. 
142 DIANE E. HOFFMANN ET AL., FINAL REPORT: FEDERAL REGULATION OF PROBIOTICS: AN ANALYSIS OF THE 
EXISTING REGULATORY FRAMEWORK AND RECOMMENDATIONS FOR ALTERNATIVE FRAMEWORKS 85–86 (Nov. 15, 
2012), http://www.law.umaryland.edu/programs/health/events/probiotics/documents/FinalWhitePaper.pdf. 
143 Id. at 86. 
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UDAP statutes generally allow a state enforcement agency, usually the attorney general, to 
obtain a court order prohibiting a seller from engaging in a particular unfair or deceptive 
practice.144 An attorney general may also ask the court to impose civil monetary penalties for 
violations of the law and to order the seller to return payments to consumers.145 For example, the 
California Attorney General used that state’s UDAP law to seek injunctive relief and civil 
penalties for allegedly unsubstantiated claims that certain ingredients in a multi-vitamin pill 
could protect against prostate cancer.146 Despite differences in state UDAP laws, it is possible for 
attorneys general to act collectively, if a national marketer is engaged in the same practices in all 
states.147 
Most statutes also allow consumers to seek similar remedies, e.g., “return of payments or 
compensation for . . . consumer loss, . . . injunction[s] against repetition of the deceptive 
                                                 
144 Carolyn L. Carter, Consumer Protection in the States: A 50-State Report on Unfair and Deceptive Acts and 
Practices Statutes, NAT’L CONSUMER LAW CENTER 6 (Feb. 2009), 
http://www.msfraud.org/law/lounge/UnfairandDeceptiveActs09.pdf. 
145 Id. 
146 See Complaint for Injunction, Civil Penalties, and Other Equitable Relief, California v. Bayer Healthcare LLC 
(Cal. Super. Ct. Oct. 26, 2010) (No. 37-2010-0010-3098-CU-MC-CTL), 
http://oag.ca.gov/system/files/attachments/press_releases/n2007_bayer_complaint.pdf. The case was settled soon 
after filing for $3.3 million.  Press Release, Cal. Office of the Att’y Gen., Brown Announces $3 Million Settlement 
over Misleading Claims that Multivitamins Can Reduce Cancer Risk (Oct. 26, 2010), http://oag.ca.gov/news/press-
releases/brown-announces-3-million-settlement-over-misleading-claims-multivitamins-can.  
147 See, e.g., Assurance of Voluntary Compliance, In re Warner Lambert Company LLC (May 11, 2004), 
http://apps.americanbar.org/antitrust/at-committees/at-state/pdf/settlements/cp/warner-lambert.pdf (describing a 
settlement with fifty states regarding promotional and marketing practices for off-label uses of a prescription drug). 
36 
 
practices, and, in most states, reimbursement for attorneys’ fees.”148 According to a 2009 report 
by the National Consumer Law Center, “[b]efore the adoption of state UDAP statutes in the 
1970s and 1980s, neither consumers nor state agencies had effective tools against fraud and 
abuse in the consumer marketplace.”149 Moreover, in most states, there was no state agency 
responsible for combatting consumer fraud and abuse.150 Claims based on common law fraud 
posed numerous obstacles to consumers who would have to, for example, establish the seller’s 
state of mind.151 Even if a consumer had a reasonable chance of success, finding an attorney to 
take the case was challenging, as few states had any provisions for reimbursing consumers for 
attorneys’ fees.152  
In recent years, consumers and public interest groups have used state UDAP laws to 
challenge food labeling and health claims. The Center for Science in the Public Interest has been 
a leader in these legal actions, often initiating a lawsuit or joining with other plaintiffs. In several 
cases the Center’s legal action preceded suits filed by state attorneys general. Examples of the 
latter include cases against Coca-Cola for making fraudulent claims about Enviga, an artificially 
sweetened green tea soda,153 and Bayer Healthcare, for claims that its One A Day men’s 
                                                 
148 See Carter, supra note 144, at 6. 
149 Id. at 5. 
150 Id. 
151 Id. 
152 Id. at 5–6. 
153 Coca-Cola marketed the drink as a weight loss product claiming that it had “negative calories” and labeled it as 
“the calorie burner” on its cans. CSPI scientists reviewed the studies relied on by Coke and determined that Enviga 
was simply “a highly caffeinated and overpriced diet soda.” Watchdog Group Sues Coke, Nestlé, for Bogus 
“Enviga” Claims, CTR. FOR SCIENCE IN THE PUB. INTEREST (Feb. 1, 2007), 
http://www.cspinet.org/new/200702011.html. In 2007, CSPI filed suit alleging that the claims “were made without 
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multivitamins reduced the risk of prostate cancer.154  While very few CSPI cases have been 
finally adjudicated, they have resulted in numerous settlements with food and dietary supplement 
manufacturers.155 Moreover, in some cases CSPI threatened but did not file suit and was able to 
negotiate a change in labeling or claims with the manufacturer.156  
In addition to the legal actions brought by CSPI and state attorneys general, consumer 
advocacy groups have brought numerous suits.  Just over the last four years consumers have filed 
“more than 150 . . . class action lawsuits against food and beverage companies.”157 Most of the 
suits have been for alleged violations of food labeling laws. Others have been for claims that, 
although not directly violating FDA food labeling laws, are alleged to be misleading under state 
                                                                                                                                                             
prior substantiation and no evidence that most consumers would realize any calorie-burning benefit.” Negowetti, 
supra note 118, at 17 (“Following the filing of this lawsuit, approximately 28 state attorneys general investigated the 
claims and ultimately settled for $650,000.”).   The company also agreed to stop making overt weight-loss claims for 
the product. Id. 
154 CSPI sued Bayer in 2009 alleging that the claims were deceptive and lacked scientific evidence. Although that 
lawsuit was dismissed on procedural grounds, while CSPI was preparing to refile “the Attorneys General of Oregon, 
California, and Illinois announced a broad settlement with Bayer on the same issues.” Litigation Project-Closed 
Cases, Ctr. for Science in the Pub. Interest, http://cspinet.org/litigation/closed.html (last visited Aug. 19, 2015). 
155 See id. (describing cases against Airborne for deceptive claims regarding its cold remedy; Aurora Dairy for 
selling its non-organic dairy products as “organic”; Dr. Pepper Snapple Group for misleading antioxidant claims on 
its labels, and General Mills for misleading claims about its “the nutritional and health qualities of its “fruit” 
snacks.). 
156 See id. (listing agreements with Pfizer Consumer HealthCare for health claims made about Centrum Dietary 
Supplements, Pepsico for claims that its IZZE sparkling juices are “natural and fortified,” Quaker Oats for claims 
that its oatmeal lowered cholesterol, and Smart Balance for claims that its Blended Butter Sticks help block 
cholesterol.). 
157 Negowetti, supra note 118, at 1. 
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law.  Many of the suits have involved foods labeled as “all natural,”158 “nutritious,” or 
“healthful.”159 Although almost none of these lawsuits have as yet been adjudicated,160 in some 
instances, the litigation has resulted in significant settlements. For instance, in 2010 the Dannon 
Company settled a false advertising lawsuit and agreed to establish a $35 million fund to 
reimburse consumers who bought its Activia and DanActive yogurts.161 The class action lawsuit 
alleged that Dannon made misrepresentations when marketing its Activia and DanActive yogurts 
by claiming nonexistent health benefits.162 The settlement may have paved the way for 
subsequent lawsuits.163 
 
IV. LIMITATIONS OF LAW AND ENFORCEMENT CAPACITY 
A. FDA 
                                                 
158 The large majority of cases (over 100) have alleged that food products have inappropriately used the label 
“natural” and that use of the term is misleading. See id. at 11. 
159 Id. at 10.  
160 Id. (as of June 2014). 
161 See Amended Stipulation of Settlement at 8, Gemelas v. The Dannon Company, Inc., 2010 WL 377068 (N.D. 
Ohio Jan. 20, 2010) (No. 1:08-cv-00236). The complaint alleged violations of two Ohio consumer protection 
statutes and breach of express warranty. Class Action Complaint, Gemelas v. The Dannon Company, Inc., 2008 WL 
824363 (N.D. Ohio Jan. 29, 2008) (No. 1:08-cv-00236).  
162 Class Action Complaint, Gemelas v. The Dannon Company, Inc.  As part of the settlement, the company agreed 
to make changes to the labeling and advertising of Activia and DanActive. Stipulation of Settlement, Gemelas v. 
The Dannon Company, Inc., 2009 WL 3197886 (N.D. Ohio Sept. 18, 2009) (No. 1:08-cv-00236).  DanActive labels 
that said the yogurt has “a positive effect on your digestive tract’s immune system” were reworded to say the yogurt 
will “interact with your digestive tract’s immune system.” Id.  
163 Negowetti, supra note 118, at 9. 
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While FDA has stepped up its actions against food and dietary supplement 
manufacturers, the agency is hindered in its ability to curtail illegal claims in part because of 
limitations on its enforcement authority and enforcement methods. FDA’s “principal 
enforcement tool” when confronted with a noncompliant food label “is to issue a Warning Letter 
to notify the manufacturer.’164 Although FDA has other enforcement mechanisms that are more 
severe, including recall, seizure, civil monetary penalties, and injunctive relief, the law 
significantly limits their use in cases of misbranding.165 As a result, according to one author, “the 
FDA primarily seeks voluntary compliance from food companies when food products are 
misleading or mislabeled” and these “Warning Letters provide little incentive or threat for 
companies to avoid or discontinue use of misleading claims on food labels.”166 
FDA is also limited in its ability to monitor health claims that bypass required premarket 
approval or nutrient content claims that are not consistent with pre-approved claims. In addition, 
because structure/function claims do not require pre-market approval, FDA is stymied in its 
ability to ensure that these claims are backed up by scientific evidence. Although dietary 
                                                 
164 Id. at 3. 
165 See id. at 4 (citing 21 U.S.C. §§ 333(f)(2)(a), 334 (a)(1), 336) (stating that “The FDA may enforce compliance 
with a recall order or impose civil monetary fines when adulteration or misbranding of food ‘will cause serious 
adverse health consequences of death,’ such as when a label is missing allergen information. The FDA may 
condemn and seize misbranded foods only after the company receives proper notice and the opportunity to respond 
and the FDA has ‘probable cause to believe . . . that the misbranded article is dangerous to health, or that the 
labeling of the misbranded article is fraudulent, or would be in a material respect misleading to the injury or damage 
of the purchaser or consumer.’ Injunctions or criminal prosecutions are rarely used for food misbranding because the 
FD&C Act expressly provides that these enforcement actions should not be initiated for ‘minor violations’ when the 
‘public interest’ may be adequately served by a written warning.”).  
166 Id.  
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supplement manufacturers must submit a notification to FDA of their claim 30 days prior to 
marketing their product, “[t]he number of manufacturers that do not submit structure/function 
claims to FDA is unknown.”167 FDA reviews all notifications submitted by dietary supplement 
manufacturers to ensure they meet “the definition of a structure/function claim. If [they do] not, 
FDA sends a letter to the manufacturer notifying it that the claim is not in compliance and 
follows up as needed.”168 A fundamental gap in the agency’s enforcement ability is that the law 
does not require manufacturers to submit the substantiation the manufacturer relied on to make 
its claim and, unlike the FTC, FDA “may not compel manufacturers to produce substantiation 
upon request.”169 As a result, FDA “has limited authority to enforce the substantiation 
requirement”170 and many manufacturers do not have adequate substantiation for their claims.171  
                                                 
167 STRUCTURE/FUNCTION CLAIMS FAIL, supra note 9, at 6 n.34.  
168 Id. at 6. 
169 Id. at 5. See also U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-11-102, FOOD LABELING: FDA NEEDS TO 
REASSESS ITS APPROACH TO PROTECTING CONSUMERS FROM FALSE OR MISLEADING CLAIMS 25 (Jan. 2011), 
http://www.gao.gov/assets/320/314473.pdf.   
170 STRUCTURE/FUNCTION CLAIMS FAIL, supra note 9, at 6.  
171 This was confirmed by the OIG in a 2012 report describing its analysis of structure/function claims and related 
substantiation documents “on a purposive sample of 127 dietary supplements marketed for weight loss or immune 
system support in retail stores and on the Internet.” Id. at 7. The OIG found that “[i]n contrast to FDA guidance, 
most substantiation was not derived from human studies,” and “10 percent of the documents appeared to have no 
significance in supporting structure/function claims.” Id. at 11–12. Furthermore, only 2% of the human studies that 
the OIG reviewed looked at the products in the sample; 4% had results that contradicted the claims made; 85% were 
not randomized clinical trials; 49% were not based on populations similar to those that would be consuming the 
supplements; and 34% focused on a disease, rather than a structure/function endpoint, and of these, 20% “had 
prohibited disease claims” including treating diseases “such as influenza, the common cold, herpes, and HIV.”  Id. at 
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Moreover, once a product is on the market, if FDA believes that a structure/function claim is not 
truthful or is misleading, in any legal proceeding the burden is on FDA to prove that the claim is 
false or misleading172 rather than on the manufacturer to prove that the claim is true and not 
deceptive. 
FDA has also been limited in its enforcement efforts by First Amendment protections of 
commercial speech. As discussed in Section III. A. above, the entire category of “qualified health 
claims” came into being as a result of litigation establishing that FDA must allow claims with 
less than substantial evidence of their truth as long as they include disclaimers. The agency 
cannot simply bar such claims unless it can meet the burdensome test of demonstrating the 
inadequacy of the disclaimer.173  
A further constraint on FDA’s enforcement capabilities is lack of resources.  In order to weed 
out noncompliant food labels and deceptive claims, FDA must rely on consumer complaints, 
proactive monitoring of Internet advertising, and physically reviewing labels at retail stores.174 
The latter two methods might root out more regulatory violations but are extremely labor-
intensive. FDA has conceded that it is overwhelmed and is “struggling to police this booming 
                                                                                                                                                             
12–16.  Ten percent of the documents submitted did not qualify as substantiation – for example, one was a “30-year-
old handwritten college term paper.” Id. at 15. 
172 Id. at 4–5. See also U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 169, at 27. 
173 See Pearson v. Shalala, 164 F.3d 650, 659 (D.C. Cir. 1999). See also Alliance for Natural Health v. Sebelius, 714 
F. Supp. 2d 48, 61–62 (D.D.C. 2010); Alliance for Natural Health v. Sebelius, 786 F. Supp. 2d 1, 13–14 (D.D.C. 
2011). 
174 While the agency conducts Internet surveillance to find supplements making such claims, it has not expanded its 
surveillance to retail stores. STRUCTURE/FUNCTION CLAIMS FAIL, supra note 9, at 3.  
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market.”175 In a letter published in The Atlantic in 2010, Michael Taylor, FDA Deputy 
Commissioner for Foods, confirmed that the agency can only reach the tip of the iceberg of 
noncompliant claims, stating that although FDA issued 20 enforcement letters to food companies 
that were marketing misbranded products in February 2010, these letters “addressed just a small 
subset of the universe of products making dubious marketing claims.”176 He further stated that 
although FDA would undoubtedly issue more letters on labeling violations, he did not see FDA 
“eradicating questionable health claims . . . any time soon,” given that FDA has “no pre-market 
review authority over such claims, and, under prevailing legal doctrines concerning ‘commercial 
free speech,’ the evidentiary requirements placed on FDA to prove that such claims are 
misleading are significant and costly to meet.”177 Moreover, he acknowledged that FDA is 
“conscious of the cleverness of marketing folks, . . . Going after them one-by-one with the legal 
and resource restraints [the agency] work[s] under is a little like playing Whac-a-Mole, with one 
hand tied behind your back.”178 
Mr. Taylor’s reference to “resource constraints” reflects a mismatch between FDA’s 
statutory responsibilities and its budget that has been noted more generally by former HHS 
Secretary Tommy Thompson. According to Thompson, who spoke at an Institute of Medicine 
meeting on Challenges for the FDA,  
the FDA has been chronically underfunded in carrying out its responsibilities for 
ensuring the safety of drugs, medical devices, and the nation’s food supply. While 
the FDA is commonly viewed as the global gold standard for consumer 
                                                 
175 Singer, supra note 23. 
176 Taylor, supra note 2. 
177 Id. 
178 Id.  
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protection, it faces stiff competition for scarce resources and over the past 20 
years has been tasked to do far more with its limited resources.179 
More recently, David Kessler, former FDA Commissioner and a board member of CSPI, 
stated that “[t]he importance of CSPI’s Stop the Lying Labels campaign is only going to grow in 




 While the FTC has recently taken a number of actions against food and dietary 
supplement manufacturers for deceptive claims, there are also significant limitations on the 
FTC’s approach to these violations of the law.  Although the FTC has a broad range of 
enforcement actions it can take against manufacturers, it frequently relies on voluntary consent 
orders to gain compliance from offending companies.181 When a company signs such an order, it 
                                                 
179 INST. OF MEDICINE, CHALLENGES FOR THE FDA: THE FUTURE OF DRUG SAFETY, WORKSHOP SUMMARY 15 
(2007), http://www.ncbi.nlm.nih.gov/books/NBK52930/pdf/TOC.pdf .  See also Associated Press, FDA 
Commissioner Margaret Hamburg: 2013 Budget Cuts Mean Less Safe Food, POLITICO (Feb. 28, 2013), 
http://www.politico.com/story/2013/02/fda-commissioner-margaret-hamburg-2013-budget-cuts-mean-less-safe-
food-88241.html. 
180 E-mail from Michael Jacobson to Diane Hoffmann, supra note 32. See also Taylor, supra note 2 (“establishing ‘a 
systematic regulatory framework to prohibit misleading health-related claims’ . . . is a noble goal and one we can 
readily embrace conceptually. But it’s a tall order, especially considering the other high-priority nutrition and food 
safety initiatives that compete for FDA’s finite resources.”). 
181 Alexandra Ledyard, Snake Oil in Your Pomegranate Juice: Food Health Claims and the FTC, 47 U.S.F. L. REV. 
783, 794 (2013). 
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need not admit that it violated the law, only that it will stop the practices identified by the 
agency.182   
Also, like FDA, the FTC has limited enforcement resources and, given the number of 
companies marketing nutritional products, it cannot investigate and prosecute every case.183 As a 
result, the FTC tends to target large companies, hoping that these actions will be a deterrent to 
other companies engaging in similar practices.  Whether this strategy deters other large 
companies is unclear, but it is unlikely that it prevents smaller businesses from advertising their 
products on the Internet with deceptive claims.  The bifurcated nutritional product industry—
with a handful of multinational corporations and hundreds of smaller businesses, a number of 
which have been described as “rogue” or “fringe” operators184—creates challenges for the 
                                                 
182 Id. at 794 & n.95 (citing Consumer Protection: Law Enforcement, U.S. FED. TRADE COMM’N (July 27, 2007), 
http://www.ftc.gov/bcp/menus/resources/enforcement.shtm).  See also Fed. Trade Comm’n, The Enforcers, GUIDE 
TO ANTITRUST LAWS, https://www.ftc.gov/tips-advice/competition-guidance/guide-antitrust-laws/enforcers  (last 
visited Aug. 19, 2015) (“If the FTC believes that a person or company has violated the law . . . , the agency may 
attempt to obtain voluntary compliance by entering into a consent order with the company. A company that signs a 
consent order need not admit that it violated the law, but it must agree to stop the disputed practices outlined in an 
accompanying complaint . . . .”)  See also Carol Brophy, An Agency “Warning Letter” Does Not a Lawsuit Make: 
Sometimes a “Warning Letter” is Really Just a Warning, SEDGWICK LAW (Nov. 2012), 
http://www.sedgwicklaw.com/an-agency-warning-letter-does-not-a-lawsuit-make-sometimes-a-warning-letter-is-
really-just-a-warning-11-13-2012/. 
183 Health Fraud and the Elderly: A Continuing Health Epidemic, Prepared Statement Before the S. Spec. Comm. on 
Aging, FED. TRADE COMM’N (Sept. 10, 2001), 
http://www.ftc.gov/sites/default/files/documents/public_statements/prepared-statement-federal-trade-commission-
dietary-supplement-fraud/healthfraud.pdf (prepared testimony of Howard Beales, Dir. of the Bureau of Consumer 
Protection, FTC). 
184 See Young, supra note 48 and accompanying text. 
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federal agencies attempting to regulate that market.  To the extent that such fringe players seek 
quick profits from deceptive practices and then shift corporate identities, they present a 
particularly difficult target for FDA and FTC enforcement efforts.185 
 
C. State consumer protection laws 
While consumers are taking advantage of state UDAP laws to bring suits against nutritional 
product manufacturers making deceptive claims, there are also problems and inefficiencies to 
such state-based action.  These problems include: 1) limits on the substantive provisions of state 
laws and differences in what they prohibit; 2) uncertainty as to how state courts will rule in these 
cases; 3) potential inconsistencies in outcomes from state to state as well as potential 
inconsistencies with federal enforcement policies; and 4) potential for over-reaching by plaintiffs 
who seek damages by bringing suits without a bona fide claim in hopes of an inflated settlement. 
As to the first of these, the National Consumer Law Center has observed that state UDAP 
statutes are too variable and constricted to be a strong deterrent to false health claims: 
The effectiveness of UDAP laws varies widely from state to state. The holes are 
glaring. Legislation or court decisions in dozens of states have narrowed the scope 
of UDAP laws or granted sweeping exemptions to entire industries. Other states 
have placed substantial legal obstacles in the path of officials charged with UDAP 
enforcement, or imposed ceilings as low as $1,000 on civil penalties. And several 
                                                 
185 See, e.g., Michael R. Ward & Michael J. Lee, Internet Shopping, Consumer Search and Product Branding, 9 J. 
PRODUCT & BRAND MGMT. 6, 8 (2000) (stating that “[b]ecause of the low costs of setting up a Web site, unreputable 
[sic] firms offering low quality products could potentially claim their products are of high quality, earn a profit 
before the ruse is uncovered, and then quickly disappear”). 
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states have stacked the financial deck against consumers who go to court to 
enforce the law themselves.186  
Also, although the large majority of the claims seem to be brought in California, private litigants 
in California (and other states) are unable to argue that an advertised health benefit is deceptive 
because it lacks substantiation. California courts have stated: 
Claims that rest on a lack of substantiation, instead of provable falsehood, are not 
cognizable under the California consumer protection laws. . . . Challenges based 
on a lack of substantiation are left to the Attorney General and other prosecuting 
authorities; private plaintiffs, in contrast, have the burden of proving that 
advertising is actually false or misleading.187 
This can be a significant burden.188 
As to the second and third problems, while over 100 cases have been brought against food 
manufacturers by litigants in state courts, almost none have been decided, creating uncertainty as 
to whether the state laws actually will be interpreted in a way that will lead to positive outcomes 
for plaintiffs, or indeed whether state courts will play a positive role in developing sound public 
policy regarding health claims. The latter is of particular concern to FDA and the FTC, which 
seek consistency across enforcement actions. The proliferation of suits, in the absence of some 
                                                 
186 Carter, supra note 144, at 3. See also NAT’L CONSUMER LAW CENTER, Appendix B: State-by-State Summaries of 
State UDAP Statutes, in CONSUMER PROTECTION IN THE STATES (Jan. 10, 2009), 
https://www.nclc.org/images/pdf/udap/analysis-state-summaries.pdf.  
187 Bronson v. Johnson & Johnson, Inc., 2013 WL 1629191, *8 (N.D. Cal. Apr. 16, 2013) (No. C 12-04184 CRB). 
See also, e.g., Scheuerman v. Nestlé Healthcare Nutrition, Inc., 2012 WL 2916827, *6 (D.N.J. July 17, 2012) (Nos. 
10-3684(FSH)(PS), 10-5628(FSH)(PS)).   
188 See, e.g. In re GNC Corp. 789 F.3d 505, 513–16 (4th Cir. 2015) (holding that a claim cannot be literally false (as 
distinct from misleading) if even one expert agrees with it). But see also Fed. Trade Comm’n v. Pantron I Corp., 33 
F.3d 1088, 1100 (9th Cir. 1994) (holding that the FTC “is not required to prove that a products is ‘wholly 
ineffective’ in order to carry its burden of showing that the seller’s representations of product efficacy are ‘false’”). 
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overall framework, potentially undermines the federal agencies’ goal of a coherent and 
authoritative set of laws and policies to guide the regulated community. From the perspective of 
risk-averse nutritional product manufacturers, inconsistencies in outcomes from state to state 
would create costly uncertainty,189 as well as the burden of having to market their products 
differently in different states. 
Finally, as to the fourth problem, the opportunity for generous damages for plaintiffs and 
contingency fees for their attorneys may lead to overreaching, i.e., bringing suits that lack 
legitimacy. A manufacturer might make a business judgment to settle such claims, despite their 
lack of merit, in order to avoid the costs associated with protracted litigation.190  
 
V. A LIMITED FEDERAL PRIVATE RIGHT OF ACTION AS A SUPPLEMENT TO GOVERNMENT 
ENFORCEMENT 
Laws that empower government agencies to protect consumers are predicated on market 
failure: in many areas, “key information necessary for consumers to make a sensible choice 
between rival brands, or to decide whether to buy the product at all, is absent.”191 Yet, this 
corrective itself can fail when the federal enforcement regime is disproportionately small, 
                                                 
189 See Roller & Pippins, supra note 111, at 447.  
190 See Brophy, supra note 182 (asserting  that plaintiffs’ attorneys often bring these suits based on FDA or FTC 
“press releases, warning letters and complaints” which do not establish the law). 




measured against the size or nature of the marketplace to be policed. “[R]egulation is only as 
good as the enforcement mechanisms underlying it.”192  
One congressional response to the problem of insufficient federal protection of statutory 
consumer rights has been to enlist state attorneys general as additional law enforcers. For 
example, the Consumer Product Safety Act authorizes state attorneys general to seek injunctive 
relief for a violation “that affects or may affect such State or its residents . . . .”193 Similar 
provisions may be found, for instance, in the Telemarketing and Consumer Fraud and Abuse 
Prevention Act,194 the Children’s Online Privacy Protection Act,195 and the Restore Online 
Shoppers’ Confidence Act.196  
A second strategy is to broaden enforcement even more, by granting rights of action to non-
governmental actors. One commentator’s summary of the rationale for private rights of action to 
vindicate civil rights laws is no less persuasive for consumer protection laws: “Even [a] . . .  
well-funded, vigorous public enforcement agency could only do so much. Private litigation 
engages a multitude of private actors to bring their resources to rooting out [unlawful 
activity].”197 
                                                 
192 J. Maria Glover, The Structural Role of Private Enforcement Mechanisms in Public Law, 53 WM. & MARY L. 
REV. 1137, 1142 (2012). 
193 15 U.S.C. § 2073(b)(1) (2012). 
194 § 6103. 
195 § 6504. 
196 § 8405. 
197 Olati Johnson, Beyond the Private Attorney General: Equality Directives in American Law 9 (Columbia Law 
Sch. Pub. Law & Legal Theory, Working Paper No. 9204, 2012), http://lsr.nellco.org/columbia_pllt/9204/. Versions 
of this argument likewise have been presented in support of unsuccessful claims for judicial recognition of an 
implied private right of action under the FTC Act. See, e.g., Carlson v. Coca-Cola Co., 483 F.2d 279, 281 (9th Cir. 
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Within the broad category of consumer protection laws, Congress has authorized private 
rights of action in, for example, the Consumer Product Safety Act,198 the Fair Credit Reporting 
Act,199 the Equal Credit Opportunity Act,200 and the Real Estate Settlements Procedures Act.201 
Within the narrower category of consumer protection laws aimed at preventing deceptive 
marketing practices, private rights of action are found in the Hobby Protection Act,202 the 
                                                                                                                                                             
1973) (Solomon, J., dissenting). It is well established that there is no private right of action under the FTC Act. See, 
e.g., Holloway v. Bristol-Myers Corporation, 485 F.2d 986 (D.C. Cir. 1973). 
198 15 U.S.C. § 2072(a) (2012) (“Any person who shall sustain injury by reason of any knowing (including willful) 
violation of a consumer product safety rule, or any other rule or order issued by the [Consumer Product Safety] 
Commission may sue any person who knowingly (including willfully) violated any such rule or order . . . .”). The 
statute provides for attorneys’ and expert witnesses’ fees. Id. 
199 “Any consumer” with respect to whom certain willful violations of the Fair Credit Reporting Act (FCRA) 
occurred may be awarded actual damages (within statutory limits), punitive damages, and costs including attorneys’ 
fees. 15 U.S.C. § 1681n (2012). Not all provisions of the FCRA are encompassed by this private right of action, 
however. See Longman v. Wachovia Bank, N.A., 702 F.3d 148, 151–52 (2d Cir. 2012). 
200 A creditor that violates statutory or regulatory requirements is liable to “an aggrieved applicant” for actual 
damages, punitive damages (within statutory limits), and costs including attorneys’ fees. 15 U.S.C. § 1691e (2012). 
201 This statute contains three private causes of action: (1) Anyone who violates certain notice requirements is liable 
to “the borrower” for actual damages, additional damages in cases of a pattern or practice of noncompliance (within 
statutory limits), and costs including attorneys’ fees. 12 U.S.C. § 2605(f) (2012). (2) Anyone who gives or receives 
kickbacks or unearned fees in connection with settlement services is liable to “the person or persons charged for the 
settlement service” for treble damages and costs including attorneys’ fees. 12 U.S.C. § 2607(d)(2), (5) (2012). (3) 
Any seller who requires the purchase of title insurance from a particular title company is liable to “the buyer” for 
treble damages. 12 U.S.C. § 2608(b) (2010). 
202 The statute specifies certain requirements for “imitation political items” and “imitation numismatic items” and 
provides that violations of these requirements are violations of the Federal Trade Commission Act. 15 U.S.C. 
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National Gold and Silver Stamping Act,203 and the Truth in Lending Act (“TILA”).204 Referring 
to TILA, the FTC has stated as follows: “Since the Act provides for a private right of action, use 
of that provision should be encouraged where the public interest and the cost benefit [sic] 
indicate that Commission action is not warranted.”205  
As discussed in Sections II and IV above, the market for nutritional products is marred by 
claims of benefit that consumers are unable to evaluate on their own and that government 
enforcement agencies are unable to police adequately—in the FDA’s case, because of limitations 
on its regulatory authority over many of these products; in both the FDA’s and FTC’s case, 
because their resources are insufficient given the breadth of their responsibilities. Nor are state 
consumer protection laws sufficient, given nationwide marketing and the difficulty of pursuing 
elusive out-of-state defendants.206 Hence, correcting abuses in this market segment entails 
                                                                                                                                                             
§ 2101(a), (b) (2012). The statute authorizes “any interested person” to seek injunctive relief and damages for 
violations and provides for costs and attorneys’ fees. 15 U.S.C. § 2102 (2012). 
203 “Customers,” as well as competitors, of precious metal manufacturers or dealers who violate certain requirements 
related to markings and tolerance from stated quality may sue for injunctive relief and damages and may be awarded 
costs and attorneys’ fees. 15 U.S.C. § 298(b) (2012).   
204 Violations of the Truth in Lending Act or its implementing regulation (adopted by the Federal Reserve Board) are 
deemed to be violations of the Federal Trade Commission Act. 15 U.S.C. § 1607(c) (2012). Individual and class 
actions are authorized against creditors who fail to comply with the Act; actual damages, statutory damages under 
certain circumstances, and costs and attorneys’ fees may be awarded. 15 U.S.C. § 1640 (2012). 
205 FED. TRADE COMM’N, OPERATING MANUAL CHAPTER 9: SPECIAL STATUTES 2, 
https://www.ftc.gov/sites/default/files/attachments/ftc-administrative-staff-manuals/ch09specialstatutes.pdf (last 
visited Aug. 19, 2015). 
206 See supra notes 48–49 and accompanying text regarding “fringe” manufacturers. 
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augmented enforcement of existing federal law, through the grant of a right of action to non-
federal parties. 
Set against this point is the argument that such a right of action poses risks to the agencies’ 
role in setting policy. State attorneys general have different constituencies and political 
incentives, “open[ing] up new outlets for state-centered policy” at variance with what federal 
agencies might perceive to be in the broader national interest.207 Non-federal litigants, for 
example, might seek to apply the broad standard of “unfair or deceptive” conduct in ways 
inconsistent with criteria developed by the FTC.208 In addition, private litigants may have 
economic incentives to bring actions primarily for the purpose of extracting settlements from 
possibly innocent defendants, akin to the concern about “strike suits” in class action securities 
fraud litigation.209  
Seeking to balance the competing considerations of expanding enforcement opportunities for 
non-federal agencies and concerns of federal agencies for developing a set of coherent laws and 
consistent policies, we propose that Congress allow a limited group of non-governmental 
plaintiffs to seek enforcement of FTC Act standards in the advertising and marketing of 
nutritional products. Creating a federal private right of action but limiting those who may bring 
actions to state attorneys general and consumer protection organizations should make it easier for 
                                                 
207 Margaret H. Lemos, State Enforcement of Federal Law, 86 N.Y.U. L. REV. 698, 698 (2011). 
208 See Henry N. Butler & Joshua D. Wright, Are State Consumer Protection Acts Really Little-FTC Acts?, 63 FLA. 
L. REV. 163, 188 (2011) (presenting evidence that state acts “may allow consumers to pursue different types of 
claims, including many that do not involve conduct that would be illegal under FTC standards for consumer 
protection.”).  
209 See, e.g., Richard F. Conklin, Why “Or” Really Means “Or”: In Defense of the Plain Meaning of the Private 
Securities Reform Act’s Safe Harbor Provision, 51 B.C. L. REV. 1209, 1210 (2010). 
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these public interest oriented plaintiffs to coordinate and work together.  This federal private 
right of action should be an attractive and more efficient alternative to bringing actions under 
each state’s consumer protection laws.  
The following are the key features of the proposed Nutritional Products Consumer Protection 
Act. Appendix A provides draft statutory language for an amendment to the Federal Trade 
Commission Act embodying these features.  
Products covered (§(a)(1) and (2)). The Act would apply to “nutritional products,” a term 
encompassing “food” and “dietary supplements.” The latter two terms would be defined as 
they are in the FD&C Act. 
Substantive requirement (§(b)). The Act would prohibit those who sell nutritional products 
in interstate commerce from engaging in “an unfair or deceptive act or practice, within the 
meaning of Section 5 of [the FTC] Act.” This incorporation of FTC Act standards allows 
the extensive body of law developed over the last century to be applied to the marketing of 
nutritional products and would deter plaintiffs from advancing novel theories of liability 
unmoored to this body of law. This provision is also drafted to ensure against 
encroachments on FDA’s authority by providing that a seller’s “use of any material that has 
been reviewed and approved by [FDA] may not be deemed to be a violation” of the Act. 
Plaintiffs authorized (§(a)(3)). As discussed above, Congress has frequently empowered 
state attorneys general to bring enforcement actions under statutes otherwise reserved for 
federal agency enforcement. We propose a similar role in this statute. Consumer protection 
lawyers in the offices of state attorneys general are experienced litigators, familiar with the 
“unfair or deceptive” standard. Given competing priorities and shrinking budgets, however, 
state attorneys general may not themselves be able to achieve the desired deterrent effect. 
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Hence, we propose that the right of action be extended to a limited group of private 
attorneys general: non-profit organizations. Non-profits such as the Center for Science in 
the Public Interest210 and the Consumer Federation of America211 have relevant expertise 
concerning food and nutrition and an organizational commitment to preventing the harm of 
false or unsubstantiated claims.212 Affording a right of action to attorneys general and 
expert non-profit organizations would harness their resources to protect consumers in a 
marketing arena badly needing additional enforcement without serious risk of “overzealous 
or otherwise socially undesirable enforcement efforts.”213 
Remedies (§(c)). Injunctive relief and damages would be authorized. To provide the 
incentive common in consumer protection legislation, the proposed Act would allow for the 
award of attorneys’ fees to a prevailing plaintiff. 
Preservation of FDA/FTC authority (§(d) and (e)(1)). The Act would require advance 
notice of an action to the FDA and FTC and would afford the two agencies an 
                                                 
210 CSPI’s litigation docket includes several cases alleging false or misleading claims in the marketing of foods and 
beverages. Litigation Project – Current Docket, CTR. FOR SCIENCE IN THE PUB. INTEREST, 
http://www.cspinet.org/litigation/current.html (last visited Aug. 19, 2015). 
211 Nutrition is one of the Federation’s areas of focus.  Nutrition, CONSUMER FED. OF AM., 
http://www.consumerfed.org/issues/food-and-agriculture/nutrition (last visited Aug. 19, 2015). 
212 We assume that suits authorized under the proposed statute would ordinarily meet the criteria for associational 
standing. See, e.g., United Food & Commercial Workers Local 751 v. Brown Group Inc., 517 U.S. 544, 553 (1996). 
213 David Freeman Engstrom, Harnessing the Private Attorney General: Evidence from Qui Tam Litigation, 112 
COLUM. L. REV. 1244, 1253 (2012). 
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unconditional right to intervene.214 All existing FDA and FTC enforcement authority 
would be unaffected. 
Non-preemption (§(e)(2)). State UDAP laws would be unaffected by the Act. 
VI. CONCLUSION 
The number of deceptive health claims being made by nutritional product manufacturers is 
large and growing. The federal agencies tasked with enforcing the laws that prohibit such claims 
are limited in their enforcement actions by statutory and First Amendment constraints but more 
significantly by insufficient resources to adequately police this market. State consumer 
protection laws are helping in some states to curtail these wrongful claims, but enforcement via 
different state laws is likely to lead to inconsistencies across states and with federal enforcement 
policies. In response to this expanding problem, we propose a limited private right of action 
under the Federal Trade Commission Act to allow state attorneys general and non-profit 
organizations to bring enforcement actions in federal court to enforce provisions of the FTC Act 
prohibiting deceptive nutritional product claims.  Such a right would augment badly needed 
protection for consumers without impairing the federal agencies’ enforcement efforts and goals. 
  
                                                 





Nutritional Products Consumer Protection Act 
15 U.S.C. §______. 
(a) For purposes of this section: 
(1) The terms “food,” “dietary supplement,” “person,” and “State” have the meaning provided 
for these terms in the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 321. 
(2) The term “nutritional product” means a food or dietary supplement. 
(3) The term “authorized plaintiff” means: 
(i) The Attorney General of a State; or 
(ii) A person that is a tax-exempt organization under § 501(c)(3) of the Internal Revenue Code. 
(b) A person may not commit an unfair or deceptive act or practice, within the meaning of 
Section 5 of this Act, in connection with the selling or offering for sale in interstate commerce of 
any nutritional product. A person’s use of any material that has been reviewed and approved by 
the Food and Drug Administration may not be deemed to be a violation of this subsection. 
(c) (1) If any person violates subsection (b) of this section, an authorized plaintiff may 
commence a civil action for injunctive relief restraining such violation and for damages in any 
United States District Court for a district in which the defendant resides or has an agent. 
 
(2) In any civil action under this subsection, the court may award to an authorized plaintiff the 




(d) (1) At least 30 days before initiating any action authorized by subsection (c) of this section, 
an authorized plaintiff shall timely provide a copy of the complete complaint to be filed and 
written notice describing such action, to the Commission and the Food and Drug Administration. 
 
(2) The written notice required under this paragraph shall, at a minimum, describe:  
(i) the identity of the parties; 
(ii) the alleged facts underlying the proceeding; and 
(iii) the relationship, if any, to any proceeding, including any rulemaking, undertaken by the 
Commission, the Food and Drug Administration, or another Federal agency. 
 
(3) In any action authorized by subsection (c) of this section, the Commission or the Food and 
Drug Administration may— 
(i) intervene in the action as a party; and 
(ii) appeal any order or judgment, to the same extent as any other party in the proceeding. 
(e) Nothing in this section impairs or preempts: 
(1) any enforcement authority of the Commission or the Food and Drug Administration; or 
(2) any cause of action available to an authorized plaintiff under State law. 
 
